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ABBREVIATIONS
AB: abortion
aCL: anticardiolipin antibody
ANA: antinuclear antibody
anti-dsDNA: anti-double-stranded DNA antibody
anti-Jo-1: anti-histidyl-tRNA synthetase antibody
anti-RNP: anti-ribonucleoprotein antibody
anti-Sm: antibody to Sm-proteins 
anti-SS-A: antibody to 3-component non-histone proteins 
anti-SS-B: antibody to phosphoprotein of RNA-polimerase III cofactor
anti-tTG: anti-tissue-transglutaminase antibody
anti-TPO: anti-thyroid peroxidase antibody
aANX: anti-Annexin V antibody
aPLs: antiphospholipid antibodies
aPS: anti-phosphatidyl serine antibody
aPE: anti-phosphatidyl ethanolamine antibody 
aPT: anti-prothrombin antibody
aβ2GPI: anti-beta-2 glycoprotein I antibody
APS: antiphospholipid syndrome
a-sperm: anti-sperm antibody
ASA: acetylsalicylic acid
ADHD: attention-deficit hyperactivity disorder 
BMI: body-mass index
β2GPI: β2 glycoprotein I
CAPS: catastrophic antiphospholipid syndrome 
CD: celiac disease
DAF/CD55: complement regulatory proteins 
ENA-Profile: antibodies against extractable nuclear antigens
ELISA: enzyme-linked immunosorbent assay
Fe: iron
FT3: free tri-jodide-thyronine
FT4: free thyroxin
GPL: IgG phospholipid level
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g: gramme 
h: hour 
HB-EGF: heparin-binding epidermal growth factor 
hCG: human chorionic gonadotrophin
Hgb: hemoglobin 
Htc: hematocrit
IF: immunofluorescent method
if: infertile
IgA: immunoglobulin A
IgE: immunoglobulin E
IgG: immunoglobulin G
IgM: immunoglobulin M
insem: insemination
IU: international unit
IUGR: intrauterine growth retardation
IVF: in vitro fertilization
IVIG: intravenous immunoglobulin
Kg: kilogramme
LA: lupus anticoagulant
L: litre
LMWH: low molecular weight heparin 
mL: millilitre 
mg: milligramme
mU: milliunit
MPL: IgM phospholipid level
μmol: micromol
μg: microgramme
ng: nanogramme
N: number of patients
PAP: placental anticoagulant proteins
PAPS: primary antiphospholipid syndrome
pg: pikogramme
pmol: pikomol
SAPS: secondary antiphospholipid syndrome
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SLE: systemic lupus erythematosus 
sp: spontaneous
st: sterile
TSH: thyroid-stimulating hormone
UFH: unfractionated heparin
U: unit
W: week of gestation
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INTRODUCTION
Autoantibodies,  autoimmune  conditions  are  frequent  causes  underlying  unsuccessful 
attempts for having a child. In a significant part of cases these are not recognised as the 
affected women have usually no other signs or symptoms suggesting an autoimmune 
disease. 
A couple is considered sterile if there is a complete inability to conceive or produce an 
offspring.  The infertility  definied  by the  absence  of  conception  after  24  months  of 
regular,  unprotected  intercourse  (1).  Of couples  in  reproductive  age,  8  to  10 % are 
sterile  and  15  to  20  %  are  infertile.  Various  genetic,  hormonal,  gynaecological, 
andrological, and immunological factors may underlie both conditions, but in about 10 
to  20  % of  cases  there  is  no  detectable  cause  (2).  In  sterile/infertile  (st/if)  female 
patients  auto-antibodies  may  be  present  which  often  escape  detection,  as  affected 
patients  have  no  signs  or  symptoms  suggesting  an  autoimmune  disease.  However, 
sterility/infertility in women of childbearing age can be considered, particularly in the 
presence of autoantibodies, as a sign of a potential autoimmune disease. By detecting 
and appropriately treating autoimmune diseases/antibodies as latent pathogenetic factors 
underlying  gestational  morbidity,  a  part  of  sterility/infertility  has  become 
extinguishable. 
Background
1.  Antibodies  and  systemic  autoimmune  diseases  -  especially  antiphospholipid 
syndrome - in relation to reproductive failures   
The antiphospholipid syndrome (APS) is a systemic autoimmune disease characterised 
by arterial and venous thrombosis, adverse outcomes in pregnancy, and raised titres of 
antiphospholipid antibodies (aPLs). The aPls are heterogenous group of autoantibodies 
that target phospholipid or phospholipid-binding proteins (3). Primary antiphospholipid 
syndrome (PAPS) is  stated  if  there is  no concurrent  autoimmune disease,  while  the 
diagnosis of secondary antiphospholipid syndrome (SAPS) is established if it  occurs 
concomitantly  with  another  autoimmune  condition  such  as  systemic  lupus 
erythematosus  (SLE)  (4).  An  acute  variant  of  the  syndrome  -  catastrophic 
antiphospholipid syndrome (CAPS) - results in widespread thrombotic microangiopathy 
and multiple organ failure (5).   
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In 1999 published Sapporo preliminary classification criteria for APS were revised in 
Sydney in 2004 (published in 2006), for establishing the diagnosis of APS, concomitant 
presence of a clinical and a laboratory criterion is required (5, 6, 7, 8) (Table I). 
The  manifestations  of  this  syndrome  can  include:  venous  thrombosis  -  deep  vein 
thrombosis,  pulmonary embolism, Budd-Chiari  syndrome,  renal vein thrombosis and 
ocular  vein  thrombosis;  arterial  thrombosis  -  stroke,  transient  ischemic  attack, 
amaurosis,  myocardial  infarction and limb ischemia (9). However,  livedo reticularis, 
cutaneous  ulcers,  Dego’s  disease,  superficial  thrombophlebitis,  Raynaud  syndrome, 
cardiac  valve  abnormality,  cardiomyopathy,  epilepsy,  migraine,  chorea,  transverse 
myelopathy,  cognitive  impairment,  aPL-associated  nephropathy,  pulmonary 
hypertension,  Addison’s  disease,  hypopituitarism,  avascular  necrosis  of  bone, 
thrombocytopenia can occur as the clinical symptom of APS (10). Apart  from these 
symptoms some less frequent aPLs neither included into the diagnostic criteria such as 
immunoglobulin  A  anti-cardiolipin  antibody  (IgA  aCL),  anti-beta-2  glycoprotein  1 
antibody  (aβ2GPI),  anti-Annexin  V  antibody  (aANX),  anti-phosphatidyl  serine 
antibody (aPS), anti-phosphatidyl ethanolamine antibody (aPE), and anti-prothrombin 
antibody (aPT) (6).
The aPLs - arise from immunoglobulin M (IgM) antibodies at low titres - are found in 
1-5 % of  healthy subjects without  thrombosis  or adverse pregnancy outcome.  Their 
prevalence increases with age and may be influenced by infections, malignancies, and 
the use of several drugs. For this reason, the definitive diagnosis of APS requires the 
presence clinical criteria with positive laboratory results at least two separate occasions 
12 weeks apart because only persistent aPLs are clinically relevant (5).
In APS - as in a hypercoagulable state - the aPLs cause platelet activation, impairment 
of the endothelial  system, facilitation of blood coagulation (3). Namely,  after having 
bound to phospholipids and phospholipid-binding proteins, aPLs hinder the function of 
those in the regulation of haemostasis. Thus they can inhibit  the functions of beta-2 
glycoprotein I, protein C, protein S, prothrombin, and Annexin V. In addition, aPLs also 
activate  endothelial  cells  leading  to  an  increased  production  of  arachidonic  acid 
metabolites, adhesion molecules and cytokines, resulting in an enhanced disposition for 
thromboembolism also by this way (11).
In pregnancy, placenta is the target organ of APS, where ischemic infarctions develop 
due to intimal proliferation, fibrinoid necrosis and intraluminal thrombosis of the spiral 
arteries (12, 13, 14). 
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Table I: Classification criteria for antiphospholipid syndrome (Sydney 2006)
Antiphospholipid syndrome is present if at least one of the clinical and one of the 
laboratory criteria that follow are met 
Clinical criteria
1. Vascular thrombosis
One or more episodes of arterial,  venous, or small vessel thrombosis in any tissue or 
organ.  Thrombosis  must  be  confirmed  by  objective  validated  criteria  (unequivocal 
findings  on  appropriate  imaging  studies  or  histopathology).  For  histopathological 
confirmation,  thrombosis  should be present  without  evidence  of  inflammation  in  the 
vessel wall. 
2. Pregnancy morbidity
a. One or more unexplained deaths of a morphologically normal fetus at or beyond the 
10th week of gestation, with normal fetal morphology documented by ultrasound or by 
direct examination of the fetus, or 
b.  One or more premature births of a morphologically normal neonate before the 34th 
week of gestation because of eclampsia or severe preeclampsia defined according to 
standard definitions, or recognized features of placental insufficiency, or
c. Three or more unexplained consecutive spontaneous abortions before the 10th week of 
gestation, with maternal anatomic or hormonal abnormalities and paternal and maternal 
chromosomal causes excluded.
Laboratory criteria
1.  Lupus anticoagulant (LA) present in plasma, on two or more occasions at least 12 
weeks apart, detected according to the guidelines of the Internal Society on Thrombosis 
and Haemostasis.
2. Anticardiolipin (aCL) antibody of IgG and/or IgM isotype in serum or plasma, present 
in medium or high titer (> 40 GPL or MPL, or > the 99 th percentile), on two or more 
occasions, at least 12 weeks apart, measured by a standardized ELISA. 
3. Anti-beta-2 glycoprotein I (aβ2GPI) antibody of IgG and/or IgM isotype in serum or 
plasma (in titer > the 99th percentile), on two or more occasions, at least 12 weeks apart, 
measured by a standardized ELISA, according to recommended procedures. 
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There are several known hypotheses relating to the pathogenic role of aPLs which elicit 
disordered  placental  function.  On  one  hand,  disequilibrium  of  arachidonic  acid 
metabolites  develops  in  the  placenta:  in  the  endothelial  cells  aPLs  impede  the 
production of prostacyclins which play an important role by helping vasodilatation and 
inhibiting platelet aggregation; and thus the result is accumulation of the procoagulant 
thromboxane A2. On the other  hand,  by binding to  placental  anticoagulant  proteins 
(PAP), aPLs inhibit the function of natural anticoagulants (15, 16) (Figure 1).
             
Figure 1: Several pathogenic mechanisms mediate aPL-associated fetal loss. Placental 
thrombosis might be induced by aPLs binding to monocytes, endothelial cells, platelets 
and plasma components of the coagulation cascade. Non-thrombotic mechanisms are 
thought to involve direct effects of aβ2GPI autoantibodies on the placenta: binding of 
aPL  to  β2GPI  expressed  on  trophoblast  membranes  might  trigger  membrane 
perturbation,  resulting in modulation of several cell  biological functions, decrease of 
trophoblast proliferation and growth, and eventually defective placentation; preliminary 
evidence  suggests  that  aPLs  might  also  affect  the  maternal  side  by  reacting  with 
endometrial  cells  in  the  decidua,  inducing  a  proinflammatory  phenotype  that  might 
interfere  with  physiological  implantation.  Abbreviations:  aPLs:  anti-phospholipid 
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autoantibodies;  β2GPI: β2 glycoprotein I.  P. L. Meroni, M. O. Borghi, E. Raschi,  F.  
Tedesco:  Pathogenesis  of  antiphospholipid  syndrome:  understanding  the  antibodies. 
Nature Reviews Rheumatology, 7., 330-339., 2011.
Immunoglobulin G (IgG) and immunoglobulin A (IgA) isotype antibodies against  β2 
glycoprotein (which is produced in large amounts also by trophoblast cells from Week 7 
of  gestation)  are  considered  much  more  specific  to  APS  than  aCL.  Namely,  aCL 
antibodies, when bound to phospholipids, overlay β2 glycoproteins so that formation of 
aβ2GPI becomes difficult. Nevertheless, serum levels of aβ2GP1 may be significantly 
elevated in aCL-negative patients with APS. A close correlation has been demonstrated 
between the presence of aβ2GPI-IgM and the occurrence of abortions during an early 
phase  of  pregnancy  (17,  18).  Annexin  V  is  one  of  the  most  significant  placental 
anticoagulant  proteins  that  can  be detected  in  a  reduced quantity  from placentas  of 
mothers with APS (15, 16). In addition, an important role is attributed to Annexin V in 
the course of undisturbed placentation as well. Therefore, antibodies produced against it 
lead to foetal loss partly by enhancing disposition for thrombosis in the placenta, partly 
by inducing apoptosis of trophoblast cells and reduction of their gonadotropin secretion. 
The risk of abortions  during the late  phase of pregnancy is  particularly high in  the 
presence of IgG isotype aANX antibodies (17, 18). In addition, in the first trimester of 
pregnancy, aPLs may induce disorders of placentation and embryonal implantation by 
directly  inhibiting  hormone production and invasion of trophoblasts  (15).  Especially 
antibodies produced against phosphatidyl serine mostly cause disorders of embryonic 
implantation  as  these  antibodies  induce  apoptosis  of  trophoblast  cells,  inhibit  cell 
proliferation  and  syncitium  formation,  decrease  human  chorionic  gonadotropin 
production  and result  defective  invasiveness  (15)  (Figure  2). The  aPLs  also  induce 
abnormalities at the maternal side of the placenta which could be found on endometrial 
biopsies. Before conception impaired endometrial differentiation and lower expression 
of  complement  regulatory  proteins  (DAF/CD55)  by  the  aPLs  may  compromise 
implantation and predispose to complement-mediated pregnancy failure.  Meroni et al 
reported that placental tissues display reduced heparin-binding epidermal growth factor 
(HB-EGF) expression in APS and aPLs bind trophoblast monolayers and significantly 
reduce HB-EGF in vitro synthesis  and secretion.  HB-EGF plays  an essential  role in 
blastocyst  implantation  and  is  downregulated  in  preeclampsia  and  hypertensive 
pregnancy  disorders  associated  with  defective  extravillous  trophoblast  invasion, 
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furthermore  heparin  can  inhibit  trophoblast  aPL-binding  and  restore  HB-EGF 
expression  in  a  dose-dependent  manner  (19)  (Figure  2).  On  the  whole,  pregnancy 
complications in APS may be mediated by several different pathogenic events such as 
thrombotic mechanisms and defective placentation caused by aPLs. But many questions 
concerning APS in pregnancy are left unanswered.   
Figure 2: aPLs might affect trophoblast cells directly. Mononuclear trophoblasts fuse 
during syncitium formation, and phosphatidylserine molecules flip to the outer layer of 
the  cell  membrane.  β2GPI  can  be  expressed  on  the  cell  membrane  of  syncitium-
trophoblast,  perhaps  due  to  binding  to  phosphatidylserine,  and  be  recognized  by 
circulating  aβ2GPI  antibodies.  Once  bound,  the  antibodies  induce  cell  membrane 
perturbation  resulting  in  modulation  of  several  biological  functions.  Abbreviations: 
aPLs:  anti-phospholipid  autoantibodies;  β2GPI:  β2 glycoprotein  I;  hCG:  human 
chorionic  gonadotrophin;  HB-EGF:  heparin-binding  EGF-like  growth  factor.  P.L.  
Meroni,  M.O.  Borghi,  E.  Raschi,  F.  Tedesco:  Pathogenesis  of  antiphospholipid  
syndrome: understanding the antibodies.  Nature Reviews Rheumatology, 7.,  330-339.,  
2011.
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Of  systemic  autoimmune  diseases,  only  the  diagnostic  criteria  of  APS  include 
gestational  morbidity  (Table  I).  However,  only  spontaneous  abortion  and premature 
birth have been included into the clinical criteria, while manifestations of the condition 
which can be brought into connection with pregnancy are much more diversified. APS 
can cause placental abruption, preeclampsia (18 %), pregnancy-induced hypertension, 
foetal death (7 %), fetal growth restriction (31 %), premature labour (43 %), stillbirth, 
and eventually also sterility (4, 12, 13, 20, 21). In various clinical studies, APS-related 
abortions occurred with an incidence of 15 to 90 % (15). APS was the underlying cause 
in  36 % and 16 % of abortions/foetal  deaths  occurring  in  early and late  pregnancy 
respectively.  When  aPLs  can  be  detected  in  a  woman  with  a  negative  history  of 
thromboembolism, the risk of an aborted pregnancy is 16 % (12). Additionally aPLs are 
reported  to  be  present  in  15  % of  women  with  recurrent  first  trimester  loss  (21). 
Furthermore,  the  incidence  of  aCL  autoantibodies  was  found  to  be  17.3  %  when 
examined in infertile women only, in contrast to 4 % in a control group with negative 
gestational history (12).
In  order  to  confirm the  latter,  detection  of  further  autoantibodies  in  sterile/infertile 
women should be sought for. Antinuclear antibody (ANA) occurs rather frequently, in 
approximately 8 to 50 %, it can be observed mostly in case of infertility, and usually it 
can  be  found  together  with  other  autoantibodies,  more  often  with  aCL  and  less 
frequently  with  anti-double-stranded  DNA  antibody  (anti-dsDNA).  Data  of  the 
literature  show  that  anti-dsDNA  may  be  present  in  2  %  of  women  with  habitual 
abortions  (14).  Of  antibodies  against  extractable  nuclear  antigens  (ENA-Profile),  3-
component antibody to non-histone proteins (anti-SS-A) (especially in association with 
elevated  serum  immunoglobulin  E  levels)  as  well  as  antibodies  against 
ribonucleoproteins (anti-RNP), when present in high titres, may lead to abortion (14, 
22).  As  APS,  that  belongs  to  acquired  thrombophilias,  is  usually  demonstrated  in 
patients with repeated events of thromboembolism which cannot be explained by other 
causes, these patients require life-long anticoagulation (2, 3). As for the therapy of APS 
demonstrated to underlie pregnancy morbidity without thromboembolism, however, no 
consensus has been attained. It matters a lot treatment of pregnants who haven’t got any 
antibodies and/or their clinical picture is not fulfil the criteria of APS (23).
When  administered  in  low  doses  (75  to  100  mg/day)  acetylsalicyclic  acid  (ASA) 
inhibits thromboxane A2 production and thus it leads to accumulation of vasodilator 
prostacyclins that is important in keeping the spiral placental arteries open (24). In a 
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placebo-controlled  study,  however,  no  significant  difference  was  found  between 
patients  with  APS  who  received  either  ASA  in  a  dose  of  75  mg/day  or  placebo, 
regarding live birth as well as maternal and foetal complications which occurred during 
pregnancy/labour (23). Opinions are also varying on the issue whether ASA alone or 
ASA plus heparin therapy is more effective (25, 26). Namely,  Farquharson et al found 
that ASA (75 mg/day) plus low molecular weight heparin (LMWH) (5000 IU/day) was 
not more effective than ASA (75 mg/day) monotherapy (25). In contrast,  Kutteh after 
having studied the  outcomes  of pregnancies  in  women with APS demonstrated  that 
ASA (81 mg/day) plus unfractionated heparin (UFH) (10000 - 20000 IU/day) therapy 
was more  effective  in  comparison  to  ASA (81 mg/day)  monotherapy (27). Also in 
relation to in vitro fertilization (IVF) in women carrying aPLs and treated with ASA 
and/or  heparin,  a  higher  number  of  conceptions  occurred  than  in  aPL-seronegative 
women who received no therapy (24). 
The  exact  mechanism  of  how  heparin  reduces  pregnancy  loss  is  still  not  fully 
understood. Apart from its anti-coagulant effect, which prevents placental infarctions, 
heparin  was  also  shown  to  bind  to  aPLs  and  render  them  biologically  inactive. 
Consequently,  by  inhibiting  aPLs  heparin  interferes  the  aPLs-induced  complement 
system activation - especially those involving C3 and C5 - is an important mechanism 
for aPLs-induced fetal loss (28, 29) (Figure 3). 
Figure 3: Heparin interferes function of polymorphonuclear leukocyte, aPLs binding, 
complement system activation and clot formation, furthermore it promotes trophoblast 
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migration too. J.E. Salmon, G. Girardi, M D. Lockshin: The antiphospholipid syndrome  
as  a  disorder  initiated  by  inflammation:  implications  for  the  therapy  of  pregnant  
patients. Nat Clin Pract Rheumatol, 3., 140-147., 2007.
Besides  protection  against  pregnancy loss,  heparin was also demonstrated  to  reduce 
obstetrical  complications  such  as  preeclampsia  and  low  birth  weight  (28,  30).  The 
combination of either LMWH or UFH with aspirin doesn’t result significant difference 
in  fetal  outcomes  and  maternal  complications  in  either  form  of  heparin.  However, 
LMWH may be a much more advantageous choice in contrast with UFH as it has got 
lower  risks  of  haemorrhage,  thrombocytopenia,  bone  loss  and  easier  administration 
(28).
To  sum up,  the  most  of  all  accepted  recommendation  for  the  treatment  of  APS in 
pregnancy is:
1.  APS with recurrent  early miscarriage  and without  previous  thrombosis:  low-dose 
ASA alone or together either UFH (5000 - 7500 IU every 12 h) or LMWH (prophylactic 
doses).
2. APS with fetal death (more than 10th weeks of gestation) or previous early delivery 
(before 34th weeks of gestation) due to severe preeclampsia or placental insufficiency 
and without previous thrombosis: low-dose ASA plus UFH (7500 - 10000 IU every 12 
h  in  the  first  trimester,  10000 IU every 12  h in  the  second and third  trimester)  or 
LMWH (prophylactic doses). 
3.  APS  with  previous  thrombosis:  low-dose  ASA plus  UFH (therapeutic  doses)  or 
LMWH (therapeutic doses) (31).
Vitamin K antagonists are teratogenic, for this reason they should be avoided in the first 
trimester of gestation. Nevertheless, warfarin after 12th weeks of gestation may be given 
only exceptional circumstances (31).
Corticosteroids are not suitable for reducing serum levels of aPLs in patients with APS; 
their use is considered reasonable, adjoining to anticoagulation, mainly in patients with 
SAPS  (13,  14).  Hasegawa  et  al found  the  combination  ASA  (81  mg/day)  plus 
prednisolone (10 mg/day) equally effective in relation to IVF both in ANA and aPL co-
positive  and  in  ANA-positive  and  aPL-negative  women  (32).  Intravenous 
immunoglobulin  (IVIG)  has  also  proven  to  be  not  more  effective  than  ASA  plus 
LMWH therapy in patients with abortions due to aPLs (33, 34). Administration of IVIG 
is recommended as an adjunct to anticoagulation in patients with severe data of history 
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(e.g.  cerebrovascular  thromboembolism,  eclampsia)  or  with  repeated  abortions 
occurring during the use of ASA and/or heparin (13, 33, 34).
2.  Autoimmune thyroiditis  and  thyroid  dysfunction  in  relation  to  reproductive 
failures
Currently,  in  the  assessment  of  women  with  reproductive  failure,  a  search  for  the 
diagnosis of both overt and latent hypothyroidism receives more and more emphasis as 
these pathological states influence not only the course of pregnancy and the fetus, but 
the development of the newborn as well (35). 
Hypothyroidism is characterized by anovulatory cycles and therefore even fertilization 
occurs  more  rarely  in  women  with  this  disease;  if  it  does  happen,  however, 
complications related to pregnancy are to be reckoned with more frequently (35.). A 
Finnish study showed significantly higher incidence of hypothyroidism among women 
with infertility and ovulation disorders in comparison to the control group (35, 36). In 
addition, women with autoimmune thyroiditis who are carriers of antithyroid peroxidase 
(anti-TPO) antibodies have a higher risk of becoming infertile even in a euthyroid state 
(37, 38), and it is also true  vice versa as anti-TPO is found in infertile women more 
frequently (39). Also, a small but already significant elevation of serum TSH level has 
been observed in anti-TPO positive infertile women as compared to a healthy control 
group (37, 38).
A survey of Klein et al showed that overt or latent hypothyroidism could be diagnosed 
in 0.3 % and 2.5 % of pregnant women respectively;  and these may lead to various 
complications of pregnancy (35, 40). Hypertension of pregnancy was found with an 
incidence of 11.6 % (3.8 % in a healthy population)  (41), including 11 % in latent 
hypothyroidism; while its incidence was 23 % in those with an overt hypothyroidism 
(42). In patients with subclinical hypothyroidism, placental abruption occurs three times 
more often, while premature labor (prior to the 32nd week of gestation) and respiratory 
distress syndrome of the newborn, both occur twice more frequently as compared to 
healthy pregnant women (43). The incidence of spontaneous abortion may even reach 
45 % in pregnant women with untreated hypothyroidism (35). A close connection is 
supposed  to  exist  between  anti-TPO  positivity  with  no  thyroid  dysfunction  and 
spontaneous  abortions,  as  several  studies  found  a  two-  to  fourfold  increase  in  the 
occurrence of spontaneous abortion in anti-TPO positive euthyroid pregnant women as 
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compared to the anti-TPO negative ones (44, 45). Two underlying causes are presumed: 
on the one hand anti-TPO antibodies occur commonly in association with other auto-
antibodies (antiphospholipid antibodies, ANA, anti-SS-A) which may also contribute to 
the cessation of pregnancy; on the other hand in the decisive majority of cases of anti-
TPO positivity there is a slightly elevated level of TSH (by 0.81 mU/L on the average) 
what already shows an impaired thyroid function, so that the thyroid gland fails to meet 
the  increased  requirements  for  its  hormones  during  pregnancy  (35).  Spontaneous 
abortions occurred in 13.8 % of women with latent hypothyroidism due to autoimmune 
thyroiditis, and that could be reduced to 3.5 % by thyroid hormone replacement (control 
group:  2.4  %).  The  occurrence  of  premature  labor  was  found  to  be  22.4  %,  what 
decreased to 7.0 % as a result of the therapy (control group: 8.2 %) (35, 39). 
Thyroid  hypofunction  in  pregnant  women  exerts  a  deleterious  effect  on  the  later 
development of their children, as two studies found a correlation between the latent or 
mild hypothyroidism observed during the mother’s pregnancy and the lower IQ values 
of their offspring (38, 40, 46, 47). In addition, the children’s IQ and their educational 
performance were similar  to those of  the control  group if  the  pregnant  women had 
received thyroid hormone substitution (38, 40). Also iodine deficiency should not be 
left  out  of  consideration  as,  in  addition  to  autoimmune  thyroiditis,  it  may  be  an 
underlying cause of hypothyroidism in pregnant women and it may exert an aggravating 
effect  not  only  on  the  intrauterine  but  also  on  the  postnatal  development  of  their 
children. In areas poor in iodine an increased incidence of attention-deficit hyperactivity 
disorder  (ADHD)  has  been  demonstrated  in  children  of  mothers  who  had 
hypothyroidism already during the first trimester of their pregnancy; this was caused by 
an insufficient  transplacental  supply of maternal  thyroid hormone for the fetal  brain 
during the period of gestation so that its development has become impaired (35, 48). 
Based  on  the  above,  the  question  emerges,  whether  a  screening  for  (autoimmune) 
thyroid  diseases  in  pregnant  women  is  required.  In  order  to  clarify  this  issue,  a 
consensus  conference  was held  in  2002,  and in  their  formulated  recommendation  a 
screening of all pregnant women was considered unnecessary, however performance of 
a TSH test was recommended in those women in child-bearing age or with pregnancy, 
whose  personal  or  family  history  included  thyroid  disease,  who  had  symptoms 
suggesting hypothyroidism,  and who had type  1 diabetes  mellitus,  organ-specific  or 
systemic  autoimmune  diseases  (49).  In  2005  the  topic  was  reconsidered  and  an 
alternative  recommendation  was  issued  according  to  which  TSH  test  should  be 
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performed  in  all  pregnant  women  (50).  However  this  has  been opposed by several 
authors who call for a first-of-all clarification of the question, which laboratory tests 
(TSH is sufficient or FT4 is also needed?) and when should be performed in pregnant 
women (51, 52). Based on the most accepted standpoint, TSH test, with an upper limit 
of  2.5  U/L,  should  be  performed  during  the  first  trimester  of  pregnancy;  if 
hypothyroidism  is  detected,  follow-up  TSH  monitoring  at  every  6  to  8  weeks  is 
recommended during a period of hormone replacement (35).  
As  there  is  a  known  relationship  between  anti-TPO  positivity  associated  with 
euthyroidism and the occurrence  of spontaneous abortions and premature births,  the 
incidences of which can be reduced significantly by levothyroxine therapy, therefore the 
timing and requirement of anti-TPO tests should also be determined in the future (35, 
39). 
3. Celiac disease in relation to reproductive failures
Celiac disease (CD) is an autoimmune process developing in genetically susceptible 
individuals exposed to the effects of certain environmental factors. 95 % of patients are 
HLA-DQ2 positive,  in addition they often carry HLA-DQ8 allele  and there may be 
other underlying genetic factors as well. However, genetic susceptibility alone is not 
enough  for  manifesting  the  pathognomonic  signs  and  symptoms  of  the  disease; 
exposition to the gluten content of wheat, barley or rye is also essential; this recognition 
is the source of the condition’s other name, gluten-sensitive enteropathy. In the sera of 
patients  there  are  auto-antibodies  of  which  anti-endomysium,  anti-gliadin  and  anti-
tissue-transglutaminase (anti-tTG) antibodies are of particular importance (53) (Figure 
4). Tissue transglutaminase enzyme that plays a part in cellular apoptosis, enters the 
extracellular space upon the cell’s injury due to the gliadin component of gluten, and 
results in the development of neoantigens and peptides with strong negative charge (53). 
By activating CD4+ T cells, these antigens induce a Th1 immune response, the effector 
phase of which implies  the destruction of intestinal  mucosa in the small  bowels by 
CD8+ T cells, natural killer cells and matrix metalloproteinases of fibroblast origin (53). 
In addition to the positive immuno-serological findings, histopathological examination 
of  the  affected  intestinal  mucosa  and  demonstration  of  villous  atrophy  are  always 
required for the diagnosis of CD (Figure 4). 
21
            
Figure 4: Image depicting the role of MHC molecule, HLA-DQ2 (or 8) contributes to 
inflammation in the gut via the production of IFN-gamma and TNF-alpha, which when 
goes unregulated, leads to tissue destruction in the intestines. R.W. DePaolo, V. Abadie,  
F. Tang, H. Fehlner-Peach, J.A. Hall,  W. Wang, E.V. Marietta,  D.D. Kasarda, T.A.  
Waldmann, J.A. Murray, C. Semrad, S.S. Kupfer, Y. Belkaid, S. Guandalini,B. Jabri:  
Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary  
antigens. Nature, 471. (7337), 220-224., 2011.
Gluten sensitivity may produce not only gastrointestinal signs and symptoms, as tissue 
transglutaminase enzyme is present, among others, in the cells of skin, muscles, nervous 
system, and liver so that it may be associated with various clinical signs and symptoms 
(54).  Of  extraintestinal  manifestations,  infertility  is  of  special  importance  because 
gluten sensitivity may be the underlying cause of delayed menarche, early menopause, 
secondary amenorrhea, infertility, habitual abortions, fetal retardation, premature birth 
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and stillbirth in women, and gonadal dysfunction and abnormalities of sperm in men 
(55, 56, 57, 58, 59, 60). 
At first in 1888 Gee reported on a reversible atrophy of intestinal mucosa of the small 
bowels leading to malabsorption in patients showing certain genetic susceptibility (61). 
The term celiac  disease was used first  time by the  Dutch pediatrician  Dicke in  the 
second half of the 1940’s; at that time gluten sensitivity was observed exclusively in 
children (61). Up to now the previous notions about CD underwent significant changes 
as forms of the disease in adult patients, not associated with gastrointestinal symptoms 
and affecting other organ systems have come more and more to the forefront. Ferguson 
compared the total  patient  population with CD to an iceberg,  the mere  small  tip  of 
which  over  the  waterline  represents  the  diagnosed  cases  showing  a  typical  clinical 
picture, while patients with “silent”, “latent” and “potential” celiac disease are located 
under the waterline (62).
The  prevalence  of  CD  in  the  general  population  is  about  0.5-1  %  with  a  female 
predominance (female/male: 2/1, 3/1), however the prevalence may vary in the different 
geographical  areas  (61).  Gluten  sensitivity  is  often  associated  with  type  1  diabetes 
mellitus, hypothyroidism, Addison’s disease, Turner and Down syndrome (61, 63). In 
spite of the more and more extended screening programs, study results unequivocally 
show that in 50-90 % of individuals with CD the disease will not be diagnosed even 
nowadays (they form the body of the iceberg), and only the tip of the iceberg continues 
to  come  into  our  field  of  vision  (61).  Undiagnosed  patients  usually  have  no 
gastrointestinal symptoms or only very mild complaints; in these cases gluten sensitivity 
may be indicated by epilepsy developing as a result of calcification in central nervous 
system;  dental  abnomalies,  endocrinologic  conditions  (e.g.  autoimmune  thyroiditis), 
polyarthritis, depression, or pathologic obstetric-gynecologic states (54, 64). 
Screening the entire population for CD would be cost-ineffective; however in certain 
situations, such as in patients with idiopathic infertility, other autoimmune pathologic 
entities  or  occurrence  of  CD  among  members  of  their  family,  the  performance  of 
screening tests has relevance (65). 
When screening subfertile and infertile women for CD, its prevalence was found to be 
2.7-3 % (54, 66) and 4-8 % (67) respectively; however Kolho et al (57, 59) found no 
difference between the prevalence in this group of patients and the general population 
(2.1 % vs. 2.0 %). Several authors (56, 58, 60, 63, 66) reported delayed menarche in 
women with CD as compared to healthy controls (Ferguson: 15 ± 2 vs. 13.5 ± 1 years; 
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Sher: 13.6  ± 1.6 vs. 12.7  ± 1.4 years; Molteni: 13.5 vs. 12.1 years) as well as early 
menopause (Ferguson: 45 ± 5.5 vs. 53 ± 1.2 years; Sher: 47.6 ± 4.4 vs. 50.1 ± 3.5 years; 
Molteni: 45.5 vs. 49.5 years). The prevalence of secondary amenorrhea was found much 
more frequent (39 % vs. 9 %) while the number of born children (1.9 ± 0.9 vs. 2.5 ± 
1.2)  lower  than  in  their  healthy  contemporaries  (58,  60,  63).  The  manifestation  of 
pathological gynecologic conditions showed no correlation with the severity of CD or 
the nutritional status of patients; however cessation of habitual abortions was observed 
upon normalization of any potential folic acid deficiency (63, 68).
Of pathological obstetric conditions, a correlation between habitual abortions and CD 
was reported at first by Morris et al in the 1970’s (59). In women with undiagnosed CD 
the prevalence of habitual  abortions has proven to be considerably higher in several 
various clinical studies (58, 59, 60, 66, 69) as compared to the group of healthy controls 
(Ogborn: 21 vs. 4 %; Molteni: 27 vs. 6.9 %; Sher: 15 vs. 5 %), however Kolho et al (67) 
demonstrated  no  significant  difference  between  the  two  groups  with  regard  to  the 
prevalence (1.6 %) of recurring abortions. The importance of the results lies in the fact 
that  in  women with already diagnosed CD the number  of habitual  abortions  can be 
reduced by gluten-free diet (Sher: 15 vs. 7 %; Ciacci: 43.3 vs. 7.7 %; Ferguson: 17.8 vs. 
9 %) (55, 56, 60, 63). The prevalence of stillbirth in women with CD is about 5.4 % that 
can be ceased completely by keeping a strict diet (56). As obstetrical complications of 
undetected  or  untreated  gluten  sensitivity,  preeclampsia,  placental  abruption  and  an 
increased number of deliveries by cesarean section have also been documented (63). 
Intrauterine  growth  retardation  (IUGR)  and  low  birth  weight  (≤ 2499  g)  can  be 
considered as independent risk factors for the future development  of certain chronic 
illnesses such as type 1 and type 2 diabetes mellitus and cardiovascular diseases (61, 
71). An extremely close and multifaceted relationship is presumed to exist between the 
presence of CD in the parents and the birth weight of their newborns. A Danish study 
showed  that  the  birth  weight  of  newborns  of  mothers  with  untreated  CD  was 
significantly lower (-238 g) as compared to those of healthy control mothers. On the 
other hand, newborns of mothers with CD who kept a gluten-free diet were delivered 
with birth weight on average higher by 67 g in comparison to newborns of healthy 
mothers examined as negative controls (63, 72, 73). The above is confirmed also by the 
observation of Ciacci et al who found that IUGR (seen in 29.4 % of untreated mothers) 
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can be ceased by gluten-free diet, and the duration of breast feeding can be prolonged 
by 2.5 months (55, 63, 73). 
In  men  CD  exerts  a  known  effect  on  gonadal  function,  as  teratozoospermia  and 
asthenozoospermia may occur in 46 % and 75 % respectively, what has proven to be 
reversible upon gluten-free diet (63, 66, 74, 75). In addition, the father’s disease may 
also  influence  the  course  of  pregnancy  and  the  expected  outcome  of  delivery 
significantly. Namely, the genomes of both parents have a decisive role in relation to 
normal embryogenesis and satisfactory placental function, and from this aspect paternal 
genes  may  conceivably  be  even  more  important  than  maternal  ones  (71,  75). 
Ludvigsson et al found the birth weight of children whose father had CD (and mother 
was healthy) significantly lower in comparison to those with a healthy father (3273 g vs. 
3596 g),  while  they  found no significant  difference  between  mothers  with  CD and 
healthy  women  in  relation  to  birth  weight  (3447  g  vs.  3596  g)  (19).  The  risk  of 
developing IUGR is fivefold  higher  in  case of fathers  with CD than in  the general 
population (11 % vs. 2.5 %) (71, 76). 
Summing up, we can state that gluten sensitivity should be taken into consideration in 
pathological  states  of  pregnancy  even  in  symptom-free  patients.  Assessment  and 
therapy of anti-tTG positive patients and follow-up of pregnancies in female patients 
with  CD  always  require  multidisciplinary  cooperation;  in  addition  we  wish  to 
emphasize that as for the outcome of pregnancy,  also male members of the couples 
should not be left out of consideration.
4. Anti-sperm antibody in relation to reproductive failures
Anti-sperm  antibodies  are  produced  both  in  men  and  in  women;  these  may  cause 
infertility  and repeated abortions occurring in early pregnancy,  as well  as they may 
result in a failure of inseminations and in vitro fertilizations (IVF) (77, 78, 79, 80, 81, 
82). In men who suffered an injury of the blood-testis barrier (e.g. vasectomy, trauma of 
the testes, local inflammation due to genital infections) antigens of the spermia become 
accessible for the immune system in the regional lymph nodes and a production of auto-
antibodies  may  start  which  can  lead  to  an  immunological  blockade  of 
spermatogenesis/spermiogenesis (77, 83). In women the genital mucosa may be injured 
during coitus or IVF, and through this a sensitization can take place and then anti-sperm 
alloantibodies may be produced (77, 83).
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IgG-type anti-sperm antibodies appear at first in the blood, and only thereafter can be 
detected in the sperm in men and in the cervical mucus in women; i.e. the reproductive 
failure  is  primarily  caused  not  by  the  locally  produced  IgA  antibodies  (77,  85). 
Regarding their effect, they may impair the viability of the spermia, their transport in 
the  uterine  tube,  their  penetration  to  the  cervical  mucus,  as  well  as  the  interaction 
between ova and spermia, and the development of the embryo.
In a Hungarian study the presence of anti-sperm antibodies detected by ELISA method 
in the sera of infertile married couples was as follows: 1. women’s sera positive to the 
sperm of their husband: 20.0 %; 2. women’s sera positive to the sperm of other men: 
33.3 %; 3. men’s sera positive to their own sperm: 7.3 %; 4. men’s sera positive for 
other men’s sperm: 15.9 % (77). When examining the cross-reactions, it occurred that a 
woman showed no reaction to the sperm of her spouse,  but reacted to the sperm of 
other(s),  on  the  other  hand  a  few  spermia  produced  positive  reactions  to  several 
women’s sera as well. All these may raise the possibility that anti-sperm antibodies are 
produced basically not against the spermia of the own partner, but to other agents with 
very  similar  antigenic  properties  (e.g.  bacteria),  and  their  titers  increase  to  a  level 
causing a reproductive failure only due to the frequent exposure to the spermia (77). In 
addition, anti-sperm antibodies can be detected in patients with SLE, in women with 
endometriosis, as well as in association with other, mostly anti-dsDNA, anti-TPO, and 
antiphospholipid auto-antibodies (78, 82, 85, 86). This can be explained by a polyclonal 
B-cell  activation  characteristic  to  autoimmune  diseases  during  which  antibodies 
showing various frequent cross-reactions are produced (78, 87). 
If a woman is positive for anti-sperm antibodies, transient use of condom by her partner 
is to be considered, what protects the patient from further antigenic stimuli for a while. 
This  method  has  a  disadvantage  that  no  treatment  duration  can  be  determined 
previously as the disappearance of the antibody shows an individual variability (it often 
may  require  even  months)  (77,  84).  In  addition,  both  in  men  and  in  women, 
immunosuppressive  (corticosteroid)  therapy,  plasmapheresis,  heterologous 
insemination, or IVF with homologous, repeatedly washed sperm may be considered 
(84, 88, 89, 90, 91). 
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AIMS OF THE INVESTIGATION
The aim of our study was to examine the antibodies and autoimmune diseases in 
relation to reproductive failures. 
1. The first aim was to establish the incidence of aPLs which are included into the APS 
diagnostic criteria (Sydney, 2004.) such as aCL and aβ2GPI among the femal patients 
with reproductive failures.
2.  The second aim was to detect  some less  frequent  aPLs neither  included into the 
diagnostic criteria such as aANX, aPS, and aPT by our femal patients.
3. The third aim of our study was to diagnose APS among patients with aPLs when 
clinical criteria were also taken into consideration and to apply anti-coagulant treatment 
among them.  
4. The fourth aim was to examine femal patients for the systemic autoimmune diseases 
apart from APS. 
5.  The  fifth  aim  of  our  study  was  to  establish  the  diagnoses  of  organ-specific 
autoimmune diseases such as autoimmune thyroiditis and celiac disease and to use their 
adequate treatment among patients with reproductive failures. 
6. The sixth aim was to detect a-sperm antibody in femal patients and to investigate its 
role in reproductive failures.
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PATIENTS AND METHODS
Patients
On the Department  of Internal Medicine of Zala County Hospital  during 88 months 
(between September 2004 and December 2011) 500 female patients (mean age: 31.4 ± 4 
years) were enrolled to our study, including 167 and 333 patients (33 % and 67 %) with 
sterility and infertility respectively. Any other causes underlying the sterility/infertility 
could be excluded or have already been eliminated previously in all of them. In addition 
to history taking and physical examination, our patients underwent the following tests: 
assay of antinuclear  antibody (ANA) by immunofluorescent  (IF) method,  as well  as 
enzyme-linked immunosorbent assays (ELISA) of anti-double-stranded DNA antibody 
(anti-dsDNA) (cut off: 25 - 120 U/mL), anticardiolipin antibody (aCL) (cut off: 10 - 100 
MPL/mL and 10 - 104 GPL/mL), antibodies against extractable nuclear antigens (ENA-
Profile) (> 1.2 U/mL) such as anti-histidyl-tRNA synthetase antibody (anti-Jo-1), anti-
ribonucleoprotein antibody (anti-RNP), antibody to Sm-proteins (anti-Sm), antibody to 
3-component  non-histone proteins  (anti-SS-A),  antibody to phosphoprotein of RNA-
polimerase III cofactor (anti-SS-B),  anti-thyroid peroxidase antibody (anti-TPO) (cut 
off:  0  -  30  U/mL),  anti-phosphatidyl  serine  antibody  (aPS)  (>  15  U/mL),  anti-
prothrombin antibody (aPT) (> 10 U/mL), anti-beta-2 glycoprotein 1 antibody (aβ2GPI) 
(>  10  U/mL),  anti-Annexin  V  antibody  (aANX)  (>  5  U/mL),  anti-tissue-
transglutaminase antibody (anti-tTG) (cut-off: 0-7 U/mL), and anti-sperm antibody (a-
sperm). We also examined 500 male patients (they are partners of our female patients) 
(mean age: 38.5 ± 3 years)  for CD, who underwent the tests of  anti-tTG (cut-off: 0-7 
U/ml)  by  ELISA.  Furthermore,  our  anti-tTG  positive  female  and  male  patients 
underwent deep duodenal biopsy for histological examination in order to confirm the 
diagnosis of CD and we carried laboratory tests out by them too, such as  hemoglobin 
(Hgb)  (123-153  g/L),  hematocrit  (Htc)  (0.36-0.46  L/L),  serum  iron  (Fe)  (8.7-27.0 
μmol/L), serum ferritin (15-150 ng/mL), serum vitamin B12 (197-866 pg/mL), serum 
folic acid (3.1-17.5 ng/mL), serum total protein (65-80 g/l), serum albumin (33-50 g/L), 
serum immunoglobulin G (IgG) (7-16 g/L), se immunoglobulin A (IgA) (0.7-4.0 g/L), 
se immunoglobulin M (IgM) (0.4-2.3 g/L). Finally, our anti-TPO positive females have 
been studied for serum thyroid-stimulating hormone (TSH) (0.4-3.2 mU/L), serum free 
tri-jodide-thyronine  (FT3)  (2.23-6.50  pmol/L)  and  free  thyroxin  (FT4)  (9.14-23.81 
pmol/L). 
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Methods
Enzyme-linked immunosorbent assays (  ELISA)  :
Anti-dsDNA  was  measured  by  ELISA  technique.  The  surface  of  a  polystyrene 
microtitration plate was sensitized for DNA overnight. On the next day, following three 
washings with PBS + 0.05 % Tween, samples were allotted to the wells of the plate 
doubled in 40x dilution. After 1-hour-long incubation and triple washings, anti-humane 
IgG/HRP  (DAKO  AS,  Denmark)  was  pipetted  into  the  wells  in  6.000x  dilution. 
Following  a  further  1-hour-long  incubation  and  washing,  o-phenylenediamine-H2O2 
substrate was applied, and then the color reaction was set by allotting 4N sulfuric acid. 
Results were measured at 492 nm with Labsystems MS Multiskan ELISA photometer 
and given in μg/mL based on a calibration curve for IgG. 
Auto-antibodies against ENA and ENA subtypes (SS-A, SS-B, Sm, RNP, Jo-1) as well 
as antibodies against TPO, tTG, sperm, and aPLs (aCL, aβ2GPI, aPS, aPT, aANX) were 
detected by a commercially available ELISA test (AUTOSTAT II ENA-Screen, anti-
SS-A,  anti-SS-B,  anti-Sm,  anti-RNP,  anti-Jo-1,  anti-TPO,  anti-tTG,  a-sperm,  aCL, 
aβ2GPI,  aPS,  aPT,  aANX;  Cogent-Hycor,  Peniciuk,  UK),  in  accordance  with  the 
instructions of the manufacturer. 
Immunofluorescent method (  IF)  :
ANA was detected on HEp-2 cell substrate (Human Epithelioma Type 2 Cells - CCL - 
23  -  American  TypeCulture  Collection)  with  a  standard  indirect  immunofluorescent 
technique.  By using a laboratory-cultured cell  line,  cell  preparations were made and 
fixed  in  acetone.  Patient  sera  were  applied  in  40x  dilution,  and  the  bound  auto-
antibodies  were  detected  with  anti-humane  IgG/FITC  (The  Binding  Site,  UK). 
Preparations  were  evaluated  with  a  Leica  Diaplan  fluorescent  microscope,  at  500x 
magnification.  Patterns  of  IF  were  created  due  to  binding  of  ANA  to  various 
components of the cell nucleus. 
Routine blood tests, TSH, FT3, FT4 and serum immunoglobulins were measured as a 
part  of  routine  diagnostics,  by  using  of  Sysmex  XP-1800I,  Vacuette  SRS  100/II, 
Modular MODU P8000 and Modular E170 systhems.
29
I. ANTIPHOSPHOLIPID ANTIBODIES AND ANTIPHOSPHOLIPID 
SYNDROME IN RELATION TO REPRODUCTIVE FAILURES
Aims
The aim was  to  establish  the  prevalence  of  aPLs which  are  included  into  the  APS 
diagnostic criteria (Sydney, 2004.) such as aCL, aβ2GPI, and detect some less frequent 
aPLs neither included into the diagnostic criteria such as aANX, aPS, and aPT, as well 
as to diagnose APS. 
Results
Twofold positive aCL was demonstrated in 27/500 patients (5.0 %) (st/if: 4/23). When 
clinical  criteria  were  also  taken  into  consideration,  3/27  PAPS could  be  diagnosed 
(Table  II,  V).  In  4/27  cases  the  APS was  associated  with  the  presence  of  another 
antibodies, such as ANA, anti-dsDNA, anti-SS-A, anti-TPO, a-sperm, however these 
women didn't suffered from another autoimmune disease, accordingly SAPS couldn't be 
confirmed, but they were observed towards SAPS (Table II, V) (Figure 5). In further 
20/27 cases the clinical picture did not fulfil the criteria of APS as 15 infertile patients 
were  examined  already after  the  first  or  second abortion  prior  to  Week  (W) 10 of 
gestation, and further 5 patients were sterile (what is not even included in the system of 
criteria for APS) (Table II). 
Number
of
patient 
Associated antibodies
(ANA, anti-dsDNA, a-sperm, 
anti-SS-A, anti-TPO)
aPL antibodies
(aβ2GPI, aPS, 
aANX, aPT)
Clinical criteria of 
APS
Diagnosis of 
APS
1/27 - - + PAPS
3/27 + - + SAPS
2/27 - + + PAPS
1/27 + + + SAPS
8/27 - - -
4/27 + - -
4/27 - + -
4/27 + + -
Table II: Female patients showing twofold anti-cardiolipin positivity
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In  addition  to  the  twofold  positive  aCL,  less  frequent  antiphospholipid  antibodies 
(aPLs) including aβ2GP1, aPS or both were present in 2/27, 3/27 and 2/27 patients, as 
well as aANX in 2/27, aANX with together aPS in 1/27 and aPS along with aPT in 1/27 
patients respectively (Figure 5). 
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aCL + a-sperm
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Figure 5:  Female patients showing twofold aCL positivity,  associated antibodies and 
aPLs (N: number of patients)
The aCL could be detected on a single occasion in 34/500 women (6.8 %) (st/if: 17/17),  
including 2/34 patients where PAPS and 1/34 patients where SAPS was suggested on 
the base of the clinical picture (Table III, V). 
Number
of
patient
Associated antibodies
(ANA, anti-dsDNA, a-sperm, 
anti-SS-A, anti-TPO, anti-tTG)
aPL antibodies
(aβ2GPI, aPS, 
aANX, aPT)
Clinical criteria of 
APS
Diagnosis of 
APS
2/34 - - + PAPS
1/34 + + + SAPS
9/34 - - -
5/34 + - -
6/34 - + -
11/34 + + -
Table III: Female patients showing one-time anti-cardiolipin positivity
Among one-time aCL-positive patients aβ2GPI, aPS, aPT and aANX could be detected 
in 1/34, 9/34, 2/34 and 1/34 patients, as well as aβ2GPI with aANX and aβ2GPI with 
aPS and aPS with aANX could be established in 2/34, 1/34 and 1/34 patients (Figure 6).
N = 27
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Figure 6:  Patients with one-time aCL, associated antibodies and aPLs (N: number of 
patients)
Considering  the  laboratory  criteria  of  APS  we  studied  the  occurence  the  aβ2GPI 
antibody.  Fifteen of the 500 (3.0 %) (st/if:  4/11) patients  was aβ2GPI positive.  We 
detected this antibody in 9/15 females with aCL-positive and 6/15 patients was aCL-
negative (Table IV).
The aβ2GPI was established one-time in 10/15 cases and twice in 5/15 cases in addition 
to we could find 2/5 aCL-negative femals in twofold aβ2GPI-positive group (Table IV). 
According to the clinical criteria of APS we could confirm 1 PAPS-patient (she was 
twofold aCL-positive too) and 2 SAPS-patiens, among them 1 was also one-time aCL-
positive and 1 patient was only twice aβ2GPI-positive (Table V).
Among  439  aCL-negative  women,  we  found  in  76/439  (17.3  %)  patients  not  only 
aβ2GPI antibody, but also such less frequent antibodies of APS (for instance aPS, aPT, 
aANX) too which not included in its laboratory criteria. The aβ2GPI antibody was one-
time positive in 2/76 cases and twofold positive in 1/76 case. 
N = 34
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st/if History Associatedantibodies Diagnosis aCL
aPL antibodies
aβ2GPI aPS aPT aANX
1 if 2 ABs (W 4,8) - +,+ +,+ - - -
2 if 2 ABs (W 7,8) - +,+ +,- - - -
3 if 2 IVFs (2 ABs, W 8,6) ANA, anti-TPO +,- +,- - - -
4 if 1 delivery, 2 ABs (W 10,9) - -,- +,- - + -
5 st 3 IVFs - +,- +,- - - +
6 if 7 IVFs (2 ABs, W 11,9) anti-SS-B SAPS +,- +,- + - -
7 if 1 procured AB (genetical cause), 2 ABs (W 4,5) ANA, anti-TPO +,- +,+ + + +
8 if 2 ABs (W5,6) - -,- +,- - - -
9 if 2 ABs (W 5,5), 1 IVF (1 twin pregnancy, AB, W 20) - PAPS +,+ +,+ + - -
10 if 1 procured AB, 5 inseminations ANA, anti-TPO +,- +,- - - +
11 st 3 inseminations, 3 IVFs - -,- +,- - - -
12 if 1 delivery, 3 ABs (W 8,12,12) ANA SAPS -,- +,+ + - -
13 st 5 inseminations, 1 IVF anti-TPO -,- +,- - - +
14 if 1 procured AB, 5 IVFs (1 AB, W 3) anti-TPO -,- +,+ - - -
15 if 2 IVFs (2 ABs, W 6,3) ANA, anti-SS-A +,+ +,- + - -
Table IV: Female patients showing aβ2GPI positivity, aCL antibody, associated antibodies and aPLs (AB: abortion, IVF: in vitro fertilization,  
W: week)
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The aPS in itself was detected in 45/76 women, aPS with aβ2GPI and aPS with aPT 
antibodies  were  verified  equally  in  1-1/76  patient.  In  six  of  76  women  aPS  was 
detectable with together aANX antibody (Figure 7). We found the aPT in 1/76 case 
respectively and aPT with aβ2GPI also in 1/76 woman. The aANX antibody alone was 
established in 16/439 patients and aANX along with aβ2GPI was in 1/76 case. Finally, 
aPS with together aPT and aANX antibodies was detectable in 1/76 patient (Figure 7). 
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Figure 7: Patients with aCL negativity and less frequent aPLs (N: number of patients)
Summing up the results of our investigations - taking the clinical and laboratory criteria 
of APS into consideration - we could demonstrate the diagnosis of APS in 11/500 (2.2 
%) patients, there are 5/11 PAPS-patients and 6/11 SAPS-patients among them (Table 
V).
 
Treatment in the follow-up period:
By the aPLs-positive patients we used the anticoagulant treatment, namely: 
1. Administration of ASA (100 mg/day orally up to week 28 of gestation) alone, when 
the patient was aPLs-positive but the clinical picture and/or laboratory criteria did not 
fulfil the diagnostic criteria of APS or the patient rejected the anticoagulant injection.
2. Administration of maintenance dose LMWH (100 U/kg/day subcutaneous up to the 
delivery)  alone,  when the patient was allergic  to acetylsalicylic  acid or the pregnant 
suffered from hematoma around fetus or hemorrhage from uterus.
N = 76
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3.  Administration  of  ASA  (100  mg/day  orally  up  to  week  28  of  gestation)  plus 
maintenance dose LMWH (100 U/kg/day subcutaneous up to the delivery).
In cases of SAPS or the patients with aPLs and antibodies of systemic autoimmune 
diseases  and/or  a-sperm  antibody  we  completed  the  anticoagulant  treatment  with 
prednisolone (20 mg/day orally in the first trimester and then tapered to a maintenance 
dose of 5 mg/day)  too.  When patients  suffered from autoimmune thyroiditis  (and/or 
latent hypothyroidism) the anticoagulant cure was completed levothyroxine too (Table 
VI).
Among the twofold aCL-positive patients 22 conceptions were develop, itemized: 2/22 
ABs and 19/22 deliveries such as 15/19 spontaneous (sp) developed pregnancies and 
4/19 pregnancies apropos of in vitro fertilization (IVF) / insemination. In addition 1/22 
pregnancy is  currently in  progress.  Furthermore  3 females  were pregnant  twice and 
there were 2 twin-pregnancies (Table VI).
In the group of females with once-time aCL positivity we could detect 15 pregnancies, 
namely  3/15  ABs,  12/15  child-births  (8/12  sp  developed  pregnancies  and  4/12 
IVF/insem pregnancies) and 1 twin-pregnancy (Table VI). 
When the aCL antibody was negative, but aβ2GPI or other  less frequent antibody of 
APS (for instance aPS, aPT, aANX) was positive, in the follow-up period there were 52 
conceptions:  13/52 ABs, 32/52 deliveries  (27/32 sp developed pregnancies  and 5/32 
IVF/insem pregnancies), 7/52 pregnancies are  currently in progress (6/7 sp developed 
pregnancies, 1/7 IVF/insem pregnancy). In addition 3 women were pregnant twice and 
5 pregnancies resulted twins (Table VII).   
Lastly, among patients with together more aPLs 8 conceptions occcured such as 1/8 AB, 
6/8  labours  (4/6  sp  developed  pregnancies  and  2/6  IVF/insem  pregnancies),  1/8 
pregnancy is currently in progress and 1 twin-pregnancy was presented (Table VIII).   
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st/if History Associatedantibodies Diagnosis aCL
aPL antibodies
aβ2GPI aPS aPT aANX
1 if 2 ABs (W 6,10) - PAPS +,+ -,- - - -
2 if 3 ABs (W 12,10,4) a-sperm SAPS +,+ -,- - - -
3 if 2 ABs (W 6,10) - PAPS +,+ -,- - - +
4 if 2 deliveries, 3 ABs (W 13,6,7) anti-dsDNA, a-sperm SAPS +,+ -,- - - -
5 if 2 ABs (W 6,10) a-sperm SAPS +,+ +,- - - +
6 if 2 ABs (W 5,5), 1 IVF (1 twin pregnancy, AB, W 20) - PAPS +,+ +,+ + - -
7 if I. 2 delivery, II. 3 ABs (W 4,7,7) anti-dsDNA SAPS +,+ -,- + - -
8 if 2 IVFs, 1 still-birth (W 29) - PAPS +,- -,- - - -
9 if 1 AB (W 24), 6 IVFs - PAPS +,- -,- - - -
10 if 7 IVFs (2 ABs, W 11,9) anti-SS-B SAPS +,- +,- + - -
11 if 1 delivery, 3 ABs (W 8,12,12) ANA SAPS -,- +,+ + - -
Table  V: Considering  the  clinical  and laboratory criteria  of  APS these patients  suffer  from PAPS or  SAPS (AB: abortion,  IVF:  in  vitro 
fertilization, W: week)
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Patients (N) Therapy
Conception 
(all)
Abortion
Delivery Pregnancy Pregnancy/Delivery
sp
IVF,
insem
sp
IVF,
insem
Twice Twin
aCL (+/+) (27/500)
ASA 6 - 3/6 3/6 - - 2 1
ASA + LMWH 9 1/9 7/9 1/9 - - - 1
ASA + levothyroxine 2 - 2/2 - - - - -
ASA + LMWH + levothyroxine 1 - - - 1/1 - - -
prednisolone 4 1/4 3/4 - - - 1 -
Summary - 22 2/22 15/22 4/22 1/22 0/22 3 2
aCL (+/-) (34/500)
ASA 5 - 1/5 4/5 - - 1/1
ASA + LMWH 7 1/7 6/7 - - - - -
ASA + levothyroxine 1 - - - - - - -
LMWH 1 1/1 - - - - - -
ASA + prednisolone 1 1/1 - - - - - -
ASA + gluten-free diet 1 - 1/1 - - - - -
Summary - 15 3/15 8/15 4/15 0/15 0/15 0 1
Table VI: Pregnancies, deliveries and abortions among patients with twofold and once-time aCL positivity (N: number of patients)
Patients (N) Therapy
Conception 
(all)
Abortion
Delivery Pregnancy Pregnancy/Delivery
sp
IVF,
insem
sp
IVF,
insem
Twice Twin
β2GPI (3/76) ASA 3 - 3/3 - - - 1 -
aPS (45/76) ASA 6 - 4/6 1/6- 1/6 - 1 1
ASA + LMWH 16 3/16 9/16 3/16 1/16 - 1
37
ASA + levothyroxine 5 5/5 - - - - - -
LMWH 1 - 1/1 - - - - -
ASA + LMWH + levothyroxine 2 - 1/2 - 1/2 - - -
ASA + LMWH + prednisolone 1 - 1/1 - - - - -
LMWH + prednisolone 1 - - - 1/1 - - -
prednisolone 1 1/1 - - - - - -
aANX (16/76) 
ASA 2 - 1/2 1/2 - - - 1
ASA + LMWH 7 - 6/7 1/7 - - 1 1
ASA + levothyroxine 2 1/2 - 1/2 - - - 1
ASA + LMWH + levothyroxine 2 - 1/2 1/2 - - - -
ASA + gluten-free diet 2 2/2 - - - - - -
aPT (1/76) ASA 1 1/1 - - - - - -
Summary - 52 13/52 27/52 5/52 6/52 1/52 3 5
Table VII: Pregnancies, deliveries and abortions among aCL-negative patients with an aPL antibody (N: number of patients)
Patients (N) Therapy
Conception 
(all)
Abortion
Delivery Pregnancy Pregnancy/Delivery
sp
IVF,
insem
sp
IVF,
insem
Twice Twin
aPS + aβ2GPI (1/76) ASA + LMWH 1 - 1/1 - - - - -
aPS + aPT + aANX (1/76) ASA + LMWH + levothyroxine 1 - 1/1 - - - - -
aPS + aANX (6/75) ASA 1 1/1 - - - - - -ASA + LMWH 5 - 2/5 2/5 1/5 - - 2
Summary - 8 1/8 4/8 2/8 1/8 0/8 - 2
Table VIII: Pregnancies, deliveries and abortions among aCL-negative patients with aPLs (N: number of patients)
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II. ANTIBODIES OF THE SYSTEMIC AUTOIMMUNE DISEASES IN 
RELATION TO REPRODUCTIVE FAILURES
Aims
The aim was to examine female patients for the systemic autoimmune diseases apart 
from APS and determine prevalence of autoantibodies such as ANA, anti-dsDNA, anti-
Jo-1, anti-Sm, anti-RNP, anti-SS-A and anti-SS-B.   
Results
The auto-antibodies for the systemic autoimmune diseases could be establish in 151/500 
(30.2 %) patients (Figure 8, 9, 10). 
In  66/500  (13.2  %)  females  these  antibodies  were  detected  without  other  auto-
antibodies for instance aPLs, anti-tTG, and anti-TPO (Figure 8). Among them we found 
ANA in itself in 52/66 women, furthermore ANA with anti-Sm, ANA with anti-SS-A 
and ANA with anti-Jo-1 antibodies  were detectable  equally in  1-1-1/66 patient.  We 
verified ANA with together anti-SS-A and anti-Sm antibodies and ANA with together 
anti-SS-A and anti-SS-B antibodies in 1-1/66 case (Figure 8). 
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Figure 8: Patients with auto-antibodies of the systemic autoimmune diseases only 
(N: number of patients)
The anti-SS-A antibody could be establish in 2/66 patients, in addition to anti-SS-B, 
anti-Jo-1 and anti-RNP antibodies were found in 1-1-1/66 female respectively. In 3/66 
N = 66
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patients the anti-dsDNA antibody in itself was presented. Finally, anti-RNP along with 
anti-SS-A and anti-SS-B antibodies were detectable in 1/66 patient (Figure 8). 
In  85/500 (17.0 %) women the auto-antibodies  of  the systemic  autoimmun diseases 
could be verify with together aPLs or auto-antibodies for organ-specific autoimmune 
diseases or a-sperm antibody (Figure 9, 10).
We could find mostly ANA (64/85),  anti-dsDNA (9/85),  and anti-SS-A (7/85) auto-
antibodies  with  each  other  and/or  aPLs  and/or  antibodies  of  the  organ-specific 
autoimmune diseases and/or a-sperm antibody such as (Figure 9, 10):
- ANA + aCL (+/-): 10/85 patients
- ANA + anti-dsDNA + aCL (+/-): 1/85 patient
- ANA + anti-TPO + aCL (+/+): 2/85 patients
- ANA + a-sperm + anti-TPO: 1/85 patient
- ANA + aCL (+/+): 1/85 patient
- ANA + a-sperm + aCL (+/-): 1/85 patient
- ANA + anti-TPO + aCL (+/-) + aβ2GPI (+/-): 1/85 patient
- ANA + aβ2GPI (+/-) + aANX: 1/85 patient
- ANA + anti-dsDNA + a-sperm + anti-TPO: 1/85 patient
- ANA + anti-TPO: 8/85 patients
- ANA + aPS: 6/85 patients
- ANA + anti-TPO + aCL (+/-) + aβ2GPI (+/+): 1/85 patient
- ANA + anti-SS-A + anti-TPO: 1/85 patient
- ANA + anti-SS-A + anti-Sm + anti- TPO: 1/85 patient
- ANA + anti-TPO + aPS + aPT + aANX: 1/85 patient
- ANA + aPS + aANX: 2/85 patients
- ANA + anti-TPO + aCL (+/-) + aPS: 1/85 patient
- ANA + aANX: 2/85 patients
- ANA + anti-TPO + aANX: 1/85 patient
- ANA + anti-Sm + anti-TPO: 1/85 patient
- ANA + aCL (+/-) + aPS: 1/85 patient
- ANA + a-sperm: 3/85 patients
- ANA + anti-SS-B + anti-TPO + a-sperm: 1/85 patient
- ANA + anti-TPO + aCL (+/-) + aβ2GPI (+/-) + aANX: 1/85 patient
- ANA + anti-Sm + anti-TPO + aANX: 2/85 patients
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- ANA + anti-tTG: 2/85 patients
- ANA + aβ2GPI (+/-) + aPS: 1/85 patient
- ANA + anti-Sm + aPS: 1/85 patient
- ANA + anti-dsDNA + aPS: 1/85 patient
- ANA + anti-TPO + aPS: 2/85 patients
- ANA + anti-SS-A + aPS: 2/85 patients
- ANA + anti-SS-A + aCL (+/+) + aβ2GPI (+/-) + aPS: 1/85 patient
- ANA + anti-RNP + anti-TPO: 1/85 patient
- ANA + anti-RNP + anti-TPO + aPS: 1/85 patient
- anti-dsDNA + aCL (+/+): 1/85 patient
- anti-dsDNA + a-sperm + aCL (+/+): 1/85 patient
- anti-dsDNA + anti-TPO + aCL (+/+): 1/85 patient
- anti-dsDNA + anti-tTG + a-sperm: 1/85 patient
- anti-dsDNA + anti-TPO: 3/85 patients
- anti-dsDNA + a-sperm + aCL (+/-): 1/85 patient
- anti-dsDNA + aCL (+/+) + aPS: 1/85 patient
- anti-SS-A + anti-TPO: 1/85 patient
- anti-SS-A + aCL (+/-) + aPS: 1/85 patient
- anti-SS-A + a-sperm: 2/85 patients
- anti-SS-A + anti-TPO + aPS: 2/85 patients
- anti-SS-A + anti-SS-B + anti-tTG: 1/85 patient
Finally, in three of the 85 cases anti-Sm and in 2/85 females anti-SS-B antibody could 
be establish along with further antibodies such as (Figure 10): 
- anti-Sm + a-sperm: 1/85 patient
- anti-Sm + anti-TPO + aPS: 1/85 patient
- anti-Sm + anti-SS-A + anti-SS-B + aCL (+/-): 1/85 patient
- anti-SS-B + aCL (+/-) + aβ2GPI (+/-) + aPS: 1/85 patient
- anti-SS-B + anti-RNP + anti-TPO: 1/85 patient
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Figure 9: Patients with ANA antibody and other antibodies (N: number of patients)
N = 64
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Figure 10:  Patients with auto-antibodies of the systemic autoimmune diseases (apart 
from ANA) and other antibodies (N: number of patients)
Treatment in the follow-up period:
In cases of patients with antibodies of systemic autoimmune diseases we applied not 
only  prednisolone  (20  mg/day  orally  in  the  first  trimester  and  then  tapered  to  a 
maintenance dose of 5 mg/day)  but also anticoagulant treatment (the same as in the 
aPLs-positive  patients)  too.  Thanks  to  application  of  these  medications  we  could 
detected 29 conception among these patients,  itemized: 5/29 ABs, 22/29 child-births 
(18/22  sp developed pregnancies and 4/22 IVF/insem pregnancies), 2/29 pregnancies 
are  currently  in  progress  (1/2  sp  developed  pregnancy,  1/2  IVF/insem  pregnancy). 
Moreover 3 women were pregnant twice and 1 pregnancy resulted twins (Table IX).   
Among such women, who had got not only antibodies of systemic autoimmune diseases 
but  also  aPLs,  antibodies  of  organ-specific  autoimmune  diseases  and/or  a-sperm 
antibody, the types of treatment and obstetrical results are represented in other chapters 
of dissertation.  
N = 21
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Patients (N) Therapy
Conception 
(all)
Abortion
Delivery Pregnancy Pregnancy/Delivery
sp
IVF,
insem
sp
IVF,
insem
Twice Twin
ANA (52/66)
ASA 5 - 4/5 - 1/5 - - -
ASA + LMWH 3 - 2/3 - - 1/3 - -
ASA + prednisolone 2 - 1/2 1/2 - - - -
LMWH 2 2/2 - - - - - -
prednisolone 8 1/8 7/8 - - - 1 1
ANA + anti-Sm (1/66) prednisolone 1 - 1/1 - - - - -
ANA + anti-SS-A (1/66) prednisolone 2 - - 2/2 - - 2 -
ANA + anti-Jo-1 (1/66) prednisolone 1 - 1/1 - - - - -
ANA + anti-SS-A + anti-Sm (1/66) prednisolone 1 - - 1/1 - - - -
anti-dsDNA (3/66) ASA + prednisolone 1 1/1 - - - - - -ASA 1 1/1 - - - - - -
anti-SS-A (1/66) prednisolone 1 - 1/1 - - - - -
anti-RNP (1/66) ASA 1 - 1/1 - - - - -
Summary - 29 5/29 18/29 4/29 1/29 1/29 3 1
Table IX: Pregnancies, deliveries and abortions among patients with antibodies of systemic autoimmune diseases (N: number of patients)
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III. AUTOIMMUNE THYROIDITIS AND THYROID DISFUNCTION IN 
RELATION TO REPRODUCTIVE FAILURES
Aims
The aim was to verify the presence of autoimmune thyroiditis and thyroid disfunction 
among female patients with reproductive failures. 
Results
The anti-TPO as the organ-specific auto-antibody of the autoimmune thyroiditis  was 
detectable in 71/500 (14.2 %) women, among them 52/71 patients were euthyroid and 
the further 19/71 patients suffered from latent hypothyroidism (Figure 11, 12).
Among the 19/71 patients suffered from latent  hypothyroidism  the anti-TPO in itself 
was detected in 9/19 women and we verified another sort of antibodies along with anti-
TPO such as (Figure 11):
- anti-TPO + ANA: 2/19 patients
- anti-TPO + ANA + anti-SS-A + anti-Sm: 1/19 patient
- anti-TPO + ANA + anti-RNP: 1/19 patient
- anti-TPO + ANA + aCL (+/+): 1/19 patient
- anti-TPO + ANA + anti-SS-B + a-sperm: 1/19 patient
- anti-TPO + anti-dsDNA + aCL (+/+): 1/19 patient
- anti-TPO + anti-SS-A: 1/19 patient
- anti-TPO + anti-RNP + anti-SS-B: 1/19 patient
- anti-TPO + aPS + anti-tTG: 1/19 patient
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Figure 11: Patients with anti-TPO and latent hypothyroidism (N: number of patients)
N = 19
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In 18/52 euthyroid cases the anti-TPO antibody could be established in itself, moreover 
in this group we studied other auto-antibodies of the systemic autoimmune and organ-
specific autoimmune diseases, aPLs and a-sperm antibody too. In our study, we could 
detect anti-TPO with together ANA in 5/52 patients, in 11/52 cases not only anti-TPO 
and ANA antibodies were detectable but also other antibodies, namely (Figure 12):
- anti-TPO + ANA + aCL (+/+): 1/52 patient
- anti-TPO + ANA + a-sperm: 1/52 patient
- anti-TPO + ANA + anti-SS-A: 1/52 patient
- anti- TPO + ANA + anti-Sm: 1/52 patient
- anti-TPO + ANA + anti-RNP: 1/52 patient
- anti-TPO + ANA + aPS: 1/52 patient
- anti-TPO + ANA + aCL (+/-) + aβ2GPI (+/-): 1/52 patient
- anti-TPO + ANA + aCL (+/-) + aPS: 1/52 patient
- anti-TPO + ANA + aCL (+/-) + aβ2GPI (+/+) + aPS + aPT + aANX: 1/52 patient
- anti-TPO + ANA + anti-Sm + anti-tTG + aANX: 1/52 patient
- anti-TPO + ANA + anti-dsDNA + a-sperm: 1/52 patient
Investigating of antibodies of the systemic autoimmune diseases except the ANA in 
3/52 women we could confirm anti-TPO antibody along with anti-dsDNA, anti-Sm and 
anti-SS-A such as (Figure 12):
- anti-TPO + anti-dsDNA: 3/52 patients
- anti-TPO + anti-Sm + aPS: 1/52 patient
- anti-TPO + anti-SS-A + aPS: 1/52 patient
As far as aPLs are concerned, including aCL and aANX antibodies were present equally 
in 2-2/52 patients, as well as aβ2GPI and aPS antibodies were verified in 1-1/52 case 
with together anti-TPO and we observed coexistence of two aPLs too (Figure 12):
- anti-TPO + aCL (+/-) + aPS: 1/52 patient
- anti-TPO + aβ2GPI (+/-) + aANX: 1/52 patient
- anti-TPO + aPS + aANX: 1/52 patient
In respect to the organ-specific auto-antibodies, the anti-tTG with anti-TPO was verified 
in 1/52 case. Last but not least, anti-TPO with a-sperm antibody could be detect in 2/52 
patients furthermore anti-TPO with together a-sperm and aCL antibodies was detected 
in 1/52 case (Figure 12).
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47
18
51111
111
1 1
1
2
2
1
1
11 1
3
1
1
1 1 1 2
anti-TPO
anti-TPO + ANA
anti-TPO + ANA + aCL (+/+)
anti-TPO + ANA + a-sperm
anti-TPO + ANA + anti-SS-A
anti-TPO + ANA + anti-Sm
anti-TPO + ANA + anti-RNP
anti-TPO + ANA + aPS
anti-TPO + ANA + aCL (+/-) + aB2GPI (+/-)
anti-TPO + ANA + aCL (+/-) + aPS
anti-TPO + ANA + aCL (+/-) + aB2GPI (+/+) + aPS + aPT + aANX
anti-TPO + ANA + anti-Sm + anti-tTG + aANX
anti-TPO + ANA + anti-dsDNA + a-sperm
anti-TPO + anti-dsDNA
anti-TPO + anti-Sm + aPS
anti-TPO + anti-SS-A + aPS
anti-TPO + aCL (+/-)
anti-TPO + aANX
anti-TPO + aB2GPI
anti-TPO + aPS
anti-TPO + aCL (+/-) + aPS
anti-TPO + aB2GPI (+/-) + aANX
anti-TPO + aPS + aANX
anti-TPO + anti-tTG
anti-TPO + a-sperm
anti-TPO + a-sperm + aCL (+/-)
Figure 12: Patients with anti-TPO and euthyroidism (N: number of patients)
In our results we noticed 18/500 (3.6 %) women suffering from latent hypothyroidism 
without  anti-TPO  antibody  and  what  is  more  among  them  there  are  9/18  patients 
without any antibodies. However in further 9/18 females with latent hypothyreosis we 
could find other antibodies (Figure 13):
- latent hypothyroidism + aCL (+/+): 2/18 patients
- latent hypothyroidism + aCL (+/-): 1/18 patient
- latent hypothyroidism + aCl (+/-) + aPS: 1/18 patient
- latent hypothyroidism + ANA: 2/18 patients
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- latent hypothyroidism + ANA + aPS: 1/18 patient
- latent hypothyroidism + ANA + anti-tTG: 1/18 patient
- latent hypothyroidism + anti-dsDNA + aCL (+/-) + a-sperm: 1/18 patient
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Figure 13: Patients with latent hypothyroidism without anti-TPO antibody (N: number 
of patients)
Treatment in the follow-up period:
Among patients suffered from latent hypothyroidism with or without anti-TPO antibody 
we could cure with levothyroxine (starting with a dose of 25 μg/day orally, and adjusted 
according to the TSH-hormone findings when required). 
Among 9/18 patients with latent hypothyroidism without anti-TPO and other antibodies 
1  patient  with  levothyroxine  plus  ASA  had  got  2  child-births  (sp  developed 
pregnancies)  and in  this  group levothyroxine  alone  resulted  further  3  deliveries  (sp 
developed pregnancies).  
In cases of patients with autoimmune thyroiditis and latent hypothyroidism along with 
antibodies of systemic autoimmune diseases and a-sperm we could 14 conceptions were 
presented, from them there were 4/14 ABs, 8/14 labour (5/8 sp developed pregnancies 
and 3/8 IVF/insem pregnancies), 2/14 pregnancies are currently in progress. Moreover 1 
female was pregnant twice and 1 pregnancy resulted twins (Table X). 
N = 18
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Patients (N) Therapy
Conception 
(all)
Abortion
Delivery Pregnancy Pregnancy/Delivery
sp
IVF,
insem
sp
IVF,
insem
Twice Twin
anti-TPO (9/19) levothyroxine 6 1/6 4/6 1/6 - - - 1levothyroxine + ASA 2 1/2 - - 1/2 - - -
anti-TPO + ANA (2/19) levothyroxine + ASA + LMWH 1 - - - 1/1 - - -
anti-TPO + ANA 
+ anti-SS-A + anti-Sm 
(1/19)
levothyroxine + ASA 1 - - 1/1 - - - -
anti-TPO + ANA 
+ anti-RNP (1/19)
levothyroxine + ASA + LMWH 1 - - 1/1 - - - -
anti-TPO + ANA 
+ anti-SS-B + a-sperm 
(1/19)
levothyroxine + ASA 1 1/1 - - - - - -
anti-TPO + anti-SS-A 
(1/19)
levothyroxine 1 1/1 - - - -
1
-
levothyroxine + prednisolone 1 - 1/1 - - - -
Summary - 14 4/14 5/14 3/14 2/14 - 1 1
Table X: Pregnancies, deliveries and abortions among patients with autoimmune thyroiditis and latent hypothyroidism along with antibodies of 
systemic autoimmune diseases and a-sperm (N: number of patients)
Patients (N) Therapy
Conception 
(all)
Abortion
Delivery Pregnancy Pregnancy/Delivery
sp
IVF,
insem
sp
IVF,
insem
Twice Twin
anti-TPO (52/71) levothyroxine 1 - 1/1 - - - - -
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levothyroxine + ASA 1 - 1/1 - - - - -
ASA 3 1/3 1/3 1/3 - - - -
LMWH 1 - 1/1 - - - - -
- 3 - 3/3 - - - - 1
anti-TPO + ANA (5/71) prednisolone 1 - 1/1 - - - - -ASA + LMWH 1 - 1/1 - - - - -
anti-TPO + ANA + anti-SS-A 
(1/71)
prednisolone 2 - 1/1 1/1 - - 1 1
anti-TPO + ANA + anti-Sm (1/71) prednisolone 2 1/2 1/1 - - - 1 -
anti-TPO + anti-dsDNA (3/71) prednisolone 1 - - 1/1 - - - -ASA + prednisolone 1 - 1/1 - - - - -
anti-TPO + a-sperm (2/71) prednisolone 1 1/1 - - - - - -ASA + LMWH 1 - 1/1 - - - - -
Summary - 19 3/19 13/19 3/19 - - 2 2
Table XI: Pregnancies, deliveries and abortions among patients with autoimmune thyroiditis and euthyroidism along with antibodies of systemic 
autoimmune diseases and a-sperm (N: number of patients)
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When anti-TPO antibody was positive and the patients with euthyroidism, in the follow-
up  period  19  concepcions  were  verified:  3/19  ABs,  16/19  child-briths  (13/16  sp 
developed pregnancies and 3/16 IVF/insem pregnancies).  In addition 2 women were 
pregnant twice and 2 pregnancies resulted twins (Table XI).   
Among such women, who with autoimmune thyroiditis (with latent hypothyroidism or 
euthyroidism) and aPLs and/or anti-tTG and/or a-sperm antibody, the types of treatment 
and obstetrical results are represented in other chapters of dissertation.  
IV. CELIAC DISEASE IN RELATION TO REPRODUCTIVE FAILURES
Aims
The anti-tTG antibody for CD was examined in female and male  patients  (they are 
partners  of  our  female  patients),  then  anti-tTG  positive  patients  underwent  deep 
duodenal biopsy for histological examination in order to confirm the diagnosis of CD 
and we carried laboratory tests out by them too.
Results
Among  male  patients  4/500  (0.8  %)  anti-tTG  positivity  has  been  demonstrated; 
histology was pathognomic for CD in all of them and the examination of sperm showed 
normal parameters in all cases (Table XII).
Partner’s history anti-tTG(U/ml)
Associated
antibodies
Deep duodenal
biopsy
Sperm 
findings
1 5 inseminations 76.1 aPS total villous atrophy physiological
2 2 ABs (W 8,8), 1 IVF 104.0 aPS total villous atrophy physiological
3 2 IVFs 467.0 - subtotal villous atrophy physiological
4
2 children 
(previous partner),
2 IVFs
114.0 - total villous atrophy physiological
Table XII: Anti-tTG antibody positivity among male patients 
(IVF: in vitro fertilization)
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Among the women we could detect  anti-tTG in 11/500 (2.2 %) cases of whom the 
diagnosis  of  celiac  disease  was  histologically  confirmed  in  8/500  (1.6  %)  patients 
(Table XIII).
Treatment in the follow-up period:
In the follow-up period success of gluten-free diet we could verify 3/8 miscarriages, 3/8 
child-births  (2/3 sp developed pregnancies  and 1/3  IVF/insem pregnancies)  and 2/8 
pregnancies are currently in progress (Table XIII).
Case reports
Case 1
In  May  2009  we  examined  the  30-year-old  female  patient  after  5  unsuccessful 
inseminations.  Her  medical  history  included  treatment  for  bronchial  asthma  in 
childhood and permanent constipation. Her laboratory findings (Hgb: 134 g/l; Htc: 0.41 
l/l;  serum Fe: 7.4 μmol/l; serum ferritin: 28.7 ng/ml; serum vitamin B12: 344 pg/ml; 
serum folic acid: 20 ng/ml; serum total protein: 69 g/l; serum albumin: 45 g/l) showed 
slight iron deficiency and selective IgA deficiency (serum IgA: 0.67 g/l; serum IgG: 
10.89  g/l;  serum  IgM:  0.84  g/l).  The  immuno-serological  tests  demonstrated  the 
positivity of anti-tTG (23 U/ml) and aCL (it could be detected only on one occasion, it 
turned  to  negative  already  after  6  weeks).  Based  on  the  subtotal  villous  atrophy 
confirmed by histological examination, we diagnosed CD at which we recommended 
further  observation  for  selective  IgA deficiency and APS.  The  patient  kept  a  strict 
gluten-free diet and received also ASA (100 mg/day orally) therapy (Table XII). 
Case 2
The 34-year-old male patient, examined in May 2009, had no complaints. However, his 
laboratory findings (Hgb: 143 g/l; Htc: 0.44 l/l; serum Fe: 4.9 μmol/l; serum ferritin: 3.4 
ng/ml; serum vitamin B12: 389 pg/ml; serum folic acid: 2.86 ng/ml; serum total protein: 
63  g/l;  serum  albumin:  41  g/l)  indicated  iron  and  folic  acid  deficiency  and  slight 
hypoproteinemia. Of his immuno-serological results, anti-tTG (76.1 U/ml) has proven 
to be positive and the aPS showed positivity on one occasion.
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st/if History anti-tTG(U/ml)
Associated
antibodies
Deep duodenal
biopsy Diagnosis Therapy
Pregnancy,
delivery, abortion
1 st 4 IVFs 46.6 a-sperm
delayed due to the 
patient’s spontaneously 
developed pregnancy 
CD ASA + gluten-free diet 1 delivery(spontaneous pregnancy)
2 if 1 delivery, 2 ABs (W 8,8) 14.2 anti-TPO, aPS total villous atrophy CD, APS,autoimmune thyroiditis
ASA + gluten-free diet 
+ levothyroxine
3 st 5 inseminations 23.0 aCL, aPS subtotal villous atrophy CD, APS, selective IgA deficiency ASA + gluten-free diet
1 IVF, 
1 delivery 
(spontaneous pregnancy)
4 if 1 delivery, 1 AB (W 18) 53.6 - negative - -
5 if 6 inseminations, 3 IVF (2 ABs, W 8,18) 57.9 - negative - -
6 if 1 procured AB, 1 AB (W 6) 33.8 aPS, aANX negative APS ASA
7 st 1 insemination 28.6 ANA subtotal villous atrophy CD, latent hypothyroidism
ASA + gluten-free diet
+ levothyroxine
1 delivery (insemination),
1 spontaneous pregnancy
8 if 3 ABs (W 8,6,6) 165.0
ANA, anti-Sm, 
anti-TPO, 
aANX
subtotal villous atrophy CD, APS,autoimmune thyroiditis
ASA + LMWH 
+ gluten-free diet 2 ABs (W 9, 5)
9 if 1 premature birth (W 29), 4 ABs (W 23,21,10,5) 427.0 - total villous atrophy
CD, Leiden mutation 
(heterozygous)
ASA + LMWH
+ gluten-free diet
10 st 3 IVFs 11.3 anti-TPO subtotal villous atrophy CD, autoimmune thyroiditis gluten-free diet 1 spontaneous pregnancy
11 if 2 ABs (W 5,5) 19.4 anti-SS-A,anti-SS-B subtotal villous atrophy CD ASA + gluten-free diet 1 AB (W 8)
Table XIV: Anti-tTG antibody positivity among female patients (AB: abortion, IVF: in vitro fertilization, W: week)
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Histological examination demonstrated total villous atrophy. The findings related to the 
sperm of this male patient  with CD showed normal  values concerning all  examined 
parameters  including the number,  shape and motion  of his  sperm cells.  The patient 
started gluten-free diet (Table XIII).
 
Curiously, the partner of the above male patient with CD was a female patient with CD, 
APS,  and  selective  IgA deficiency,  also  diagnosed  by us  (Table  XII,  XIII)).  Their 
genetic testing detected HLA-DQ2 homozygous state in both of them. The couple with 
gluten sensitivity commonly continued keeping a strict gluten-free diet. In November 
2009 - as no spontaneous conception occurred up to that time - she underwent IVF 
which ended with no success. 
In  March 2010  another  IVF was  planned,  however  the  menstruation  of  the  female 
patient  delayed  and her pregnancy test  indicated  spontaneously conceived gravidity. 
The pregnant woman with CD underwent regular medical and gynecologic follow-ups 
and no overt state of deficiency (iron, vitamin B12, folic acid) could be detected during 
her pregnancy. In October 2010, in the 26th week of her pregnancy her anti-tTG has 
already proven to be negative (0.52 U/ml).  In January 2011 she delivered a healthy 
newborn (birth weight: 2980 g) in the 38th week of her gestation. 
V. ANTI-SPEM ANTIBODY IN RELATION TO REPRODUCTIVE FAILURES
Aims
The aim was to establish the prevalence of a-sperm antibody in female patient with 
reproductive failures.
Results
The a-sperm antibody could be presentable in 49/500 (9.8 %) cases and it  could be 
detect alone in 21/49 women. In further 28/49 patients a-sperm was concomitant with 
other antibodies such as (Figure 14): 
- a-sperm + ANA: 3/28 patients
- a-sperm + ANA + aCL (+/-): 2/28 patients
- a-sperm + ANA + anti-TPO: 1/28 patient
- a-sperm + ANA + anti-dsDNA + anti-TPO: 1/28 patient
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- a-sperm + ANA + anti-SS-B + anti-TPO: 1/28 patient 
- a-sperm + aCL (+/+): 2/28 patients
- a-sperm + aCL (+/-): 2/28 patients
- a-sperm + aCL (+/-) + aPT: 1/28 patient
- a-sperm + aCL (+/+) + aPS: 2/28 patients
- a-sperm + aCL (+/-) + aANX: 1/28 patient
- a-sperm + aPS: 2/28 patients
- a-sperm + aANX: 1/28 patient
- a-sperm + aPS + aANX: 1/28 patient
- a-sperm + anti-dsDNA + aCL (+/+): 1/28 patient
- a-sperm + anti-dsDNA + aCL (+/-): 1/28 patient
- a-sperm + anti-dsDNA + anti-tTG: 1/28 patient
- a-sperm + anti-SS-A: 2/28 patients
- a-sperm + anti-Sm: 1/28 patient
- a-sperm + anti-TPO: 2/28 patients
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a-sperm + anti-TPO
Figure 14: Patients with a-sperm antibody (N: number of patients)
N = 49
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Treatment in the follow  -up period  :
When the patient was a-sperm positive alone or with ANA or anti-SS-A antibody, there 
were  19  conceptions  such  as:  2/19  ABs,  16/19  deliveries  (13/16  sp  developed 
pregnancies, 3/16 IVF/insem pregnancies)  and 1/19 pregnancy is currently in progress 
furthermore  we  verified  1  twice-pregnant  woman  and  3 pregnancies  resulted  twins 
(Table XIV).
Among such women,  who had got  not  only a-sperm and antibodies  of  autoimmune 
diseases but also aPLs, anti-TPO and/or anti-tTG, the types of treatment and obstetrical 
results are represented in other chapters of dissertation.  
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Patients (N) Therapy
Conception 
(all)
Abortion
Delivery Pregnancy Pregnancy/Delivery
sp
IVF,
insem
sp
IVF,
insem
Twice Twin
a-sperm (21/49)
prednisolone 12 - 9/12 2/12 1/12 - 1 2
prednisolone + ASA 1 - 1/1 - - - - -
ASA 1 1/1 - - - - - -
ASA + LMWH 1 - 1/1 - - - - -
a-sperm + ANA (3/49) prednisolone 3 - 2/3 1/3 - - - 1
a-sperm + anti-SS-A (2/49) prednisolone 1 1/1 - - - - - -
Summary - 19 2/19 13/19 3/19 1/19 - 1 3
Table  XIV:  Pregnancies,  deliveries  and  abortions  among  patients  with  a-sperm antibody  alone  and  a-sperm with  antibodies  of  systemic 
autoimmune diseases (N: number of patients)
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DISCUSSION OF THE DISSERTATION
Of couples in reproductive age, 8 to 10 % are sterile and 15 to 20 % are infertile. A 
couple  is  sterile  when  no  pregnancy  occurs  within  2  years.  In  case  of  infertility, 
conception  takes  place;  however  due to any case,  no live neonate  is  born from the 
pregnancy/pregnancies. 1 to 2 % of women in childbearing age have habitual abortions, 
or  at  least  3  consecutive  spontaneous  miscarriages.  Underlying  both  sterility  and 
infertility,  there  may  be  various  genetic,  hormonal,  gynecologic,  andrologic  or 
immunologic  factors;  however  no detectable  cause  is  found in  a  significant  part  of 
cases. (Auto)antibodies may be present in both members of the couples, causing failure 
of attempts to have children. Often these are not recognized, as the affected individuals 
have  no  signs  or  symptoms  suggesting  any  autoimmune  disease.  Nevertheless, 
sterility/infertility in women of childbearing age who have autoantibodies is considered 
as a potential sign of an autoimmune disease. 
Due to  the  importance  of  the  issue,  we believed  that  studying  of  the  immunologic 
processes underlying sterility and infertility is worth to be the topic of a PhD thesis. 
Antiphospholipid  antibodies  and  antiphospholipid  syndrome  in  relation  to 
reproductive failures
In our work with sterile/infertile women, we studied not only the presence of aCL and 
aβ2GPI antibodies which are included in the diagnostic criteria of APS, but also the 
presence of further aPLs (aANX, aPS, and aPT) which are not among the criteria, but 
can often be found in the background of pathologic pregnancies. 
Antibodies included in the laboratory criteria of APS (aCL, aβ2GPI):
The aCL antibody could be detected on two occasions in 27/500 (5.0 %) (st./if.: 4/23) 
patients; in addition to aCL further aPLs were also present in 11/27 of them. The aCL 
antibody could be observed on one occasion in 34/500 (6.8 %) (st./if.: 17/17) female 
patients; in this group other aPLs were found in addition to aCL in 17/34 patients. The 
presence of aβ2GPI antibodies could be demonstrated in 15/500 (3.0 %) (st./if.: 4/11) 
patients (in 9/15 aCL-positive and in 6/15 aCL-negative women): aβ2GPI proved to be 
positive once or twice in 10/15 and 5/15 patients respectively.
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The following aPLs were observed among the aCL-negative patients:
Less frequent aPLs detected in 76/439 (17.3 %) of the 439/500 aCL-negative female 
patients: 3 aβ2GPI; 45 aPS; 1 aPS + aβ2GPI; 1 aPS + aPT; 6 aPS + aANX; 1 aPT; 1 
aPT + aβ2GPI; 16 aANX; 1 aANX + aβ2GPI; 1 aPS + aPT + aANX.
We found aPL in a total of 137/500 women during the study; while taking both clinical 
and  laboratory  criteria  of  APS  into  consideration,  the  diagnosis  of  APS  could  be 
established in 11/500 (2.2 %) patients, including 5/11 and 6/11 patients with PAPS and 
SAPS respectively. 
However,  we  used  anticoagulant  therapy  during  the  follow-up  period  not  only  in 
patients with confirmed APS, but also in those who did not fulfill the diagnostic criteria 
of the disease completely. Consequently, 22 pregnancies (2/22 ABs, 19/22 deliveries; 
1/22 pregnancy is currently in progress) occurred in patients with aCL positivity on two 
occasions, and there were 15 pregnancies (3/15 ABs, 12/15 childbirths) in women who 
were aCL-positive on one occasion. In the group of aCL antibody-negative women who 
were at the same time carriers of one of the less frequent aPLs, a total of 52 conceptions 
occurred  (13/52 ABs,  32/52  deliveries;  7/52  pregnancies  are  currently  in  progress). 
Finally, among aCL-negative women who were at the same time carriers of multiple 
less frequent sPLs, 8 pregnancies were observed (1/8 AB, 6/8 childbirths, 1/8 pregnancy 
is  currently  in  progress).  Having  taken  the  successfully  delivered  pregnancies  into 
consideration, we also demonstrated that ASA + LMWH therapy has proven to be the 
most effective treatment in patients with aPLs. 
Summing up, it can be stated that the previously undetected APS may be an important 
etiologic factor underlying sterility/infertility;  furthermore an appropriate therapy can 
terminate the adverse effects of aPLs that cause morbidities of pregnancy (92, 93, 94). 
Antibodies of the systemic autoimmune diseases in relation to reproductive failures
In  addition  to  APS,  we also  looked in  our  female  patients  for  other  autoantibodies 
(ANA, anti-dsDNA, anti-Jo-1, anti-Sm, anti-RNP, anti-SS-A, anti-SS-B) suggesting the 
presence of other systemic autoimmune diseases. 
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The presence of autoantibodies was observed in a total of 151/500 (30.2 %) patients; 
these antibodies  occurred as  single in  66/151 patients,  and in  the remaining 85/151 
cases  they were detected  in  association  with  aPLs and/or  with antibodies  of  organ-
specific autoimmune diseases (anti-tTG, anti-TPO). 
In this group of patients we used not only immunosuppressive prednisolone therapy, but 
also anticoagulant therapy in several cases, due to which 29 conceptions occurred (5/29 
ABs, 22/29 childbirths; 2/29 pregnancies are currently in progress).
The results  of  our study showing that  ANA, anti-dsDNA and anti-SS-A antibodies, 
particularly  together  with  aPLs,  occur  very  frequently  in  patients  with  reproductive 
problems are in  accordance  with the international  literature.  Although we could not 
diagnose any systemic autoimmune disease among our patients, as the specific clinical 
signs and symptoms characteristic to those were not present, nevertheless anticoagulant 
therapy seems to be justified in the presence of autoantibodies,  as this  may make a 
successful childbirth possible (92, 93, 94)
Autoimmune  thyroiditis  and  thyroid  dysfunction  in  relation  to  reproductive 
failures
We  screened  the  women  with  reproductive  failure  also  for  thyroiditis  and  thyroid 
dysfunction. 
Autoimmune thyroiditis:
Anti-TPO antibodies were found in a total of 71/500 (14.2 %) patients, including 52/71 
euthyroid  women  and  19/71  patients  with  latent  hypothyroidism.  Among  the  9/19 
women  with  latent  hypothyroidism,  9/19  had  only  anti-TPO,  while  in  10/19  other 
antibodies  were also present  in  addition  to  the anti-TPO. In the group of  euthyroid 
patients anti-TPO positivity alone occurred in 18/52, while aPLs, antibodies of systemic 
autoimmune diseases, anti-tTG and a-sperm antibodies could also be detected in 34/52 
patients. 
Thyroid dysfunction without autoimmune thyroiditis:
Among our patients, 18/500 (3.6 %) women had latent hypothyroidism without being a 
carrier of anti-TPO antibodies. Furthermore, no autoantibody at all could be found in 
9/18 patients; in the other 9/18 patients ANA, anti-dsDNA, aPLs (aCL, aPS), anti-tTG 
and a-sperm antibodies could be observed in addition to the latent hypothyroidism. 
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Patients  with  latent  hypothyroidism  received  levothyroxine  substitution  during  the 
follow-up period;  checks of TSH levels  were performed in the euthyroid  anti-TPO-
positive women. Among the women with autoimmune thyroiditis, 14 pregnancies were 
observed (4/14 ABs, 8/14 childbirths; 2/14 pregnancies are currently in progress). In the 
anti-TPO-positive  euthyroid  women  a  total  of  19  conceptions  (3/19  ABs,  16/19 
childbirths)  occurred.  A total  of  5  childbirths  occurred  among  patients  who had no 
detectable  anti-TPO  or  any  other  antibodies  in  association  with  their  thyroid 
dysfunction. 
Our results  demonstrate  that  levothyroxine  substitution  should  start  already prior  to 
conception in patients with latent or overt hypothyroidism and it should be continued, 
with close monitoring of TSH levels during pregnancy. As sterility/infertility may also 
be caused by autoimmune thyroiditis in a euthyroid patient, regular checking of TSH in 
TPO-positive women of reproductive age should be underlined; in these cases the upper 
limit of TSH is 2.5 U/L (93, 94). 
Celiac disease in relation to reproductive failures
Determination of anti-tTG, required for the detection of CD was performed not only in 
our female patients but in their male partners as well, and then deep duodenal biopsy 
and  laboratory  tests  seeking  malabsorption  were  also  done in  the  anti-tTG positive 
patients. 
Among  men,  anti-tTG  positivity  was  observed  in  4/500  (0.8%)  patients,  and  the 
histological  examination  confirmed  CD  in  all  of  them.  Among  women,  anti-tTG 
positivity was detected in 11/500 (2.2 %), and the diagnosis of CD could be confirmed 
by histological examination in 8/500 (1.6 %) of them. As a result of a strict gluten-free 
diet, 8 pregnancies (3/8 ABs, 3/8 childbirths, 2/8 pregnancies are currently in progress) 
developed  during  the  follow-up.  No premature  birth  and no IUGR of  the  newborn 
babies occurred among the mothers with CD. 
A curiosity of our study: we could demonstrate previously unrecognized CD in both 
members  of  a  couple,  and  then  at  a  gluten-free  diet  they  had,  via  spontaneous 
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conception a healthy offspring in 2011 (95, 96). At a gluten-free diet, no positivity was 
shown in the child by periodic anti-tTG tests. With the examination of blood and tissue 
(umbilical cord and placenta) samples obtained from parents and child, we could make 
a contribution to an international genetic study of non-HLA genes underlying CD. 
Anti-sperm antibody in relation to reproductive failures
In our female patients, we also performed the examination of a-sperm antibodies which 
may be an emerging underlying etiologic factor of reproductive failure. 
A-sperm could be detected in 49/500 (9.8 %) patients, of them no other antibody was 
present  in  21/49,  while  in  the  further  28/49  women  also  autoantibodies  could  be 
observed in addition to a-sperm. 
In  a-sperm positive  patients,  with  the  use  of  prednisolone,  and added anticoagulant 
therapy in some cases, 19 conceptions (2/19 ABs, 16/19 deliveries, 1/19 pregnancy is 
currently in progress) occurred. 
Although a-sperm is a hetero-antibody in women, nevertheless the results of our study 
confirmed  that  it  is  frequently  associated  with  autoantibodies  (it  has  been observed 
mostly  with  ANA,  anti-dsDNA, anti-TPO,  and aPLs);  therefore  immunosuppressive 
therapy may be justified in patients with sterility/infertility (94). 
In summary, it can be stated: the results of our series of examinations shed light on the 
fact that it is worthwhile to examine sterile/infertile couples for autoimmune diseases, 
autoantibodies, as the confirmation and appropriate treatment of these may lead to a 
successful  childbirth.  The  results  of  our  PhD  work  have  been  published  in  both 
Hungarian and international literature (92, 93, 94, 95, 96), and successful conception of 
155 children occurred during our treatments. As far as we know, we published on this 
topic as first in Hungary. 
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NEW OBSERVATION
1. As first in Hungary, we introduced an organized assessment of infertile couples 
for autoimmune diseases in an outpatient  basis within the frame of specialist 
clinics of immunology. 
2. Our outpatient  clinics of this  purpose attained not only a regional  but also a 
trans-border  role  in  a  short  time.  The  number  of  patients  with  reproductive 
failure examined and treated by us has reached, and currently exceeded 500. In 
addition to infertile couples from Zala County, a significant part of our patients 
arrived from Budapest, from all Trans-Danubian counties, on several occasions 
from even farther  areas  of the country (Csongrád, Bács-Kiskun, Hajdú-Bihar 
counties), moreover from abroad (Austria, Slovakia, Romania) as well. 
3. During our activity we could establish a very good and successful professional 
relationship with the representatives of the partner specialties (Clinical Genetics, 
Obstetrics-Gynecology,  Endocrinology,  Gastroenterology,  Laboratory 
Diagnostics), and we formed an interdisciplinary working group. 
4. Our results obtained in relation to APS illuminate the necessity of an assessment 
of infertile women not only in pathological states which fulfill  the diagnostic 
criteria of APS, but it is justified on the one hand already earlier (after one or 
two abortions in the first trimester,  or also related to infertility),  on the other 
hand in the presence of other pathological states which are not included to the 
criteria (e.g. history of preeclampsia, premature delivery, low-weight newborn). 
5. Our findings demonstrate that antibodies not included to the laboratory criteria 
of  APS  (aPS,  aANX)  have  a  significant  relevance  in  the  development  of 
pregnancy-related morbidities,  so that in the presence of these an appropriate 
anticoagulant therapy may result in childbirth. 
6. Although the infertile women had no clinical symptoms suggesting autoimmune 
diseases (no systemic autoimmune disease, except APS, could be diagnosed); 
nevertheless  their  chances  for  childbirth  were  improved  by  low-dose 
corticosteroid therapy, administered – often in association with anticoagulation – 
due to their auto-antibody positivity. 
7. Thyroid diseases occurred frequently among our patients; therefore we strongly 
recommend  screening  for  autoimmune  thyroiditis  and thyroid  dysfunction  in 
women with reproductive failure. 
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8. By presenting the case of a couple with celiac disease, which is considered a 
rarity in Hungary, we wish to call attention to the fact that celiac disease in both 
women  and  men  may  be  the  underlying  cause  of  pathological  states  of 
pregnancy,  so  that  a  screening  of  both  members  of  the  infertile  couples  is 
justified. Engaged in an international scientific research, with samples obtained 
from the parents and their offspring (sera and tissues taken from the placenta and 
the umbilical cord in relation to the delivery), we could made a contribution to a 
more exact elucidation of the genetic background of celiac disease. 
9. Our  study  exemplifies  well  that  anti-sperm  antibodies  appear  often  in 
association with other auto-antibodies, so that an administered anticoagulation 
and/or corticosteroid therapy may prove to be effective in this group of patients. 
10. Our results support the fact that immunological assessment should be a part of 
the assessment of infertile couples, in addition the treatment and care of couples 
with demonstrated antibody positivity requires a multidisciplinary cooperation 
of  the  representatives  of  partner  specialties  in  order  to  attain  a  successful 
childbirth. 
The  attachment  bellow  includes  the  tableau  portraits  of  a  part  of  the  children 
successfully delivered as a result of our research and therapy. 
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ÖSSZEFOGLALÁS
A fogamzóképes párok 8-10 %-a steril, 15-20 %-a pedig infertilis. Steril a pár, ha két 
éven belül nem következik be graviditás. Infertilitás esetén a fogantatás megtörténik, 
azonban  a  terhesség(ek)ből  valamilyen  ok  miatt  mégsem  születik  élő  újszülött.  A 
reproduktív korú nők 1-2 %-a habituális vetélő, vagyis legalább 3 spontán vetélés követi 
egymást. Mind a sterilitás, mind pedig az infertilitás hátterében különböző genetikai, 
hormonális, nőgyógyászati, andrológiai, immunológiai tényezők állhatnak, azonban az 
esetek  jelentős  részében nincs  kimutatható  ok.  Sikertelen  gyermekvállalást  okozva a 
párok  mindkét  tagjánál  (auto)antitestek  lehetnek  jelen.  Ezek  gyakran  nem kerülnek 
felismerésre,  hiszen  az  érintetteknek  autoimmun  betegségre  utaló  tünete  nincsenek. 
Ugyanakkor a reproduktív korban lévő nőknél a sterilitást/infertilitást - autoantitestek 
jelenlétében - autoimmun kórképek lehetséges tüneteként értékeljük. 
A  téma  fontossága  miatt  éreztük  úgy,  hogy  a  sterilitás,  infertilitás  hátterében  álló 
immunológiai folyamatok vizsgálata PhD dolgozat témájaként szolgálhat. 
(A  magyar  nyelvű  összefoglalóban  használatos  rövidítések  az  angol  nyelvű  PhD 
dolgozat rövidítések jegyzékében találhatókkal egyezőek.)
Antifoszfolipid antitestek és antifoszfolipid szindróma a reproduktív elégtelenségek 
hátterében
Munkánk során steril/infertilis nők körében vizsgáltuk nemcsak az APS diagnosztikus 
kritériumában  foglalt  aCL  és  aβ2GPI  antitestek,  hanem  a  kritériumok  között  nem 
szereplő, a terhességi kórállapotok hátterében viszont gyakran fellelhető további aPL-ek 
(aANX, aPS, and aPT) jelenlétét. 
Az APS laboratóriumi kritériumai között szereplő antitestek (aCL, a  β  2GPI)  : 
Az aCL-antitest két alkalommal 27/500 (5,0 %) (st/if: 4/23) betegnél volt kimutatható, 
közöttük 11/27 esetben az aCL mellett további aPL-ek is jelen voltak. Az aCL-antitest 
egyszer  volt  észlelhető 34/500 (6,8 %) (st/if:  17/17) nőbetegnél,  ebben a csoportban 
17/34 esetben találtunk az aCL mellett más aPL-eket is. Az aβ2GPI antitestet 15/500 
(3,0 %) (st/if: 4/11) nőnél tudtuk igazolni (9/15 aCL-pozitív és 6/15 aCL-negatív nőnél): 
10/15 betegnél egyszer, 5/15 betegnél pedig kétszer bizonyult az aβ2GPI pozitívnak. 
Az aCL-negatív betegeknél észlelt aPL-ek:
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A 439/500  aCL-negatív  nőbeteg  között  76/439  (17,3  %)  esetben  tudtunk  kimutatni 
ritkább aPL-t: 3 aβ2GPI, 45 aPS, 1 aPS + aβ2GPI, 1 aPS + aPT, 6 aPS + aANX, 1 aPT,  
1 aPT + aβ2GPI, 16 aANX, 1 aANX + aβ2GPI, 1 aPS + aPT + aANX. 
Vizsgálatunk során összesen 137/500 nőnél találtunk aPL-t, közöttük - az APS klinikai 
és  laboratóriumi  kritériumait  is  figyelembe  véve  -  11/500  (2,2  %)  betegnél  tudtuk 
kimondani az APS diagnózisát: 5/11 PAPS és 6/11 SAPS került leírásra.
A követési időszakban azonban nemcsak az igazolt APS-ás betegeknél, hanem a kórkép 
diagnosztikus  kritériumait  maradéktalanul  nem  teljesítők  körében  is  alkalmaztuk  az 
antikoaguláns kezelést. Így a két alkalommal aCL-pozitív betegeknél 22 terhesség (2/22 
AB, 19/22 szülés,  1/22  jelenleg  is  zajló  terhesség),  az  egy alkalommal  aCL-pozitív 
nőknél pedig 15 terhesség (3/15 AB, 12/15 szülés) jött létre. Az aCL-antitest negatív, 
azonban egy-egy ritkább aPL-t hordozó nők csoportjában összesen 52 fogantatás történt 
(13/52 AB, 32/52 szülés, 7/52 jelenleg is zajló terhesség). Végezetül az aCL-negatív, de 
egyidejűleg több ritka aPL-t hordozóknál 8 terhességet észleltünk (1/8 AB, 6/8 szülés, 
1/8 jelenleg is zajló terhesség). A sikeresen kihordott terhességeket figyelembe véve mi 
is  igazoltuk,  hogy  aPL-ek  jelenlétekor  az  ASA  +  LMWH  kezelés  bizonyul  a 
legeffektívebbnek. 
Összegzésként  elmondhatjuk,  hogy  sterilitás/infertilitás  hátterében  fontos  kóroki 
tényező lehet az addig fel nem fedezett APS, továbbá megfelelő kezeléssel a terhességi 
morbiditásokat előidéző aPL-ek káros hatásai megszűntethetőek.
Szisztémás  autoimmun  kórképekre  jellemző  auto-antitestek  a  reproduktív 
elégtelenségek hátterében
Nőbetegeinknél az APS-en kívül, más szisztémás autoimmun betegségekre utaló auto-
antitesteket (ANA, anti-dsDNA, anti-Jo-1, anti-Sm, anti-RNP, anti-SS-A, anti-SS-B) is 
kerestünk. 
Összesen 151/500 (30,2 %) betegnél észleltük auto-antitestek jelenlétét: 66/151 esetben 
ezek  az  antitestek  önmagukban,  a  fennmaradó  85/151  esetben  aPL-ekkel  és/vagy 
szervspecifikus autoimmun betegségek auto-antitestjeivel  (anti-tTG, anti-TPO) együtt 
tudtuk kimutatni. 
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Ebben a betegcsoportban nemcsak immunszupresszív prednisolon kezelést folytattunk, 
hanem több esetben antikoaguláns kezelést is, melyeknek köszönhetően 29 fogantatás 
(5/29 AB, 22/29 szülés, 2/29 jelenleg is zajló terhesség) következett be.
Vizsgálatunk eredményei - melyek szerint reprodukciós problémával küzdők körében az 
ANA, az anti-dsDNA és az anti-SS-A antitestek előfordulása különösen aPL-ek mellett 
nagyon  gyakori  -  a  szakirodalommal  egybehangzóak.  Betegeinknél  szisztémás 
autoimmun betegséget diagnosztizálni nem tudtunk, hiszen az ezekre specifikus klinikai 
tünetek  valamennyiüknél  hiányoztak,  azonban  auto-antitestek  jelenlétében  az 
immunszupresszív  kezelésnek  létjogosultsága  van,  hiszen  ezzel  a  sikeres 
gyermekvállalás lehetővé válik.
Autoimmun thyreoiditis és pajzsmirigy diszfunkció a reproduktív elégtelenségek 
hátterében
A reproduktív elégtelenségben szenvedő nőket autoimmun thyreoiditis és pajzsmirigy 
diszfunkció irányában is vizsgáltuk. 
Autoimmun thyreoiditis:
Munkánk  során  anti-TPO  antitestet  összesen  71/500  (14,2  %)  betegnél  találtunk, 
közülük 52/71 nő euthyreoid volt, 19/71 betegnél latens hypothyreosis volt igazolható. 
A  latens  hypothyreosisban  szenvedők  között  9/19  nőnél  csak  anti-TPO  volt  jelen, 
további  10/19  esetben  anti-TPO  mellett  más  antitestek  is  észlelhetőek  voltak.  Az 
euthyreoid  betegek  csoportjában  18/52  anti-TPO-pozitivitás  fordult  elő  önmagában, 
34/52  betegnél  az  anti-TPO  mellett  aPL-ek,  szisztémás  autoimmun  betegségek 
antitestjei, anti-tTG és a-sperm is kimutatható volt. 
Pajzsmirigy diszfunkció autoimmun thyreoiditis nélkül:
Beteganyagunkban 18/500 (3,6 %) nő szenvedett latens hypothyreosisban anélkül, hogy 
anti-TPO  antitestet  hordozott  volna.  Sőt  9/18  betegnél  egyáltalán  nem  találtunk 
semmilyen auto-antitestet,  további 9/18 esetben a latens hypothyreosis mellett  ANA, 
anti-dsDNA, aPL-ek (aCL, aPS), anti-tTG és a-sperm antitest észlelhető volt.
A  követési  időszakban  latens  hypothyreosisban  szenvedő  betegeinknél  levothyroxin 
szubsztitúciót  végeztünk,  euthyreoid  anti-TPO-pozitív  nőknél  TSH-ellenőrzést 
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folytattunk. Autoimmun thyreoiditisben szenvedő nők között 14 terhességet (4/14 AB, 
8/14 szülés, 2/14 jelenleg is zajló terhesség) észleltünk. Az anti-TPO-pozitív euthyreoid 
nőknél összesen 19 fogantatás (3/19 AB, 16/19 szülés) történt. Azoknál a betegeinknél, 
akiknél  a  pajzsmirigy diszfunkció mellett  sem anti-TPO, sem más  antitest  nem volt 
kimutatható, összesen 5 szülés következett be.
Eredményeink  bizonyítják,  hogy  latens  vagy  manifeszt  hypothyreosis  esetén  a 
levothyroxin pótlást már a fogantatást megelőzően el kell kezdeni és a terhesség alatt 
szoros TSH ellenőrzés mellett folytatni kell. Euthyreosissal járó autoimmun thyreoiditis 
is  lehet  oka  sterilitásnak/infertilitásnak,  így a  reproduktív  életkorban levő anti-TPO-
pozitív nők rendszeres TSH-kontrollja fontos, ezekben az esetekben a TSH felső határa 
2,5 U/L.
Lisztérzékenység a reproduktív elégtelenségek hátterében
A CD igazolásához szükséges anti-tTG meghatározást nemcsak nőbetegeinknél, hanem 
férfi partnereiknél is elvégeztük, majd az anti-tTG-pozitív betegeknél mély duodenum 
biopszia és felszívódási zavar irányában laboratóriumi vizsgálatok is történtek. 
A férfiaknál 4/500 (0,8 %) esetben észleltük az anti-tTG pozitivitását, a szövettani lelet 
mindegyiküknél kórjelző volt CD-re. A nőknél 11/500 (2,2 %) anti-tTG-pozitivitás volt 
kimutatható, közülük 8/500 (1,6 %) betegnél tudtuk a CD diagnózisát szövettani lelettel 
is alátámasztani.  A követési időszakban szigorú gluténmentes diéta eredményeként 8 
terhesség alakul ki (3/8 AB, 3/8 szülés, 2/8 jelenleg is zajló terhesség); a CD-s anyáknál 
koraszülés, újszülöttjeiknél IUGR nem fordult elő. 
Vizsgálatunk kuriózumát adja, hogy egy pár mindkét tagjánál tudtuk igazolni az addig 
fel nem ismert CD-t, majd gluténmentes diéta mellett spontán fogantatásból 2011-ben 
egészséges  gyermekük  született.  A  gyermeknél  gluténtartalmú  diéta  mellett  az 
időszakosan elvégzett anti-tTG vizsgálat pozitivitást eddig nem jelzett. A szülőktől és a 
gyermektől  nyert  vér-  és szövetminta  (köldökzsinór  és placenta)  vizsgálatával  a CD 
hátterében álló non-HLA-gének nemzetközi genetikai kutatásához tudtunk hozzájárulni.
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Spermium elleni antitest a reproduktív elégtelenségek hátterében
Nőbetegeinknél a sikertelen gyermekvállalás hátterében kórokként felmerülő a-sperm 
antitest vizsgálatát is elvégeztük. 
Az a-sperm 49/500 (9,8 %) esetben volt kimutatható. Közöttük 21/49 nőnél más antitest 
nem volt jelen, a további 28/49 betegnél viszont az a-sperm mellett auto-antitestek is 
észlelhetőek voltak. 
Az a-sperm-pozitív betegeinknél alkalmazott prednisolonnal és néhány esetben ennek 
antikoaguláns kezeléssel történő kiegészítésével 19 fogantatás (2/19 AB, 16/19 szülés, 
1/19 jelenleg is zajló terhesség) következett be.
Az a-sperm nőkben hetero-antitest,  azonban vizsgálatunk eredményei  igazolták, hogy 
gyakran társul auto-antitestekkel (főként ANA, anti-dsDNA, anti-TPO, aPL-ek mellett 
észlelhető),  ezért  sterilitás/infertilitás  esetén  az  immunszupresszív  kezelésnek 
létjogosultsága van.
Eredményeink  rávilágítanak  arra,  hogy  steril/infertilis  párokat  érdemes  autoimmun 
betegségek,  auto-antitestek  irányába  vizsgálni,  hiszen  ezek  bizonyítása  és  megfelelő 
kezelése sikeres gyermekvállaláshoz vezethet. PhD munkánk eredményét mind magyar, 
mind nemzetközi szakfolyóiratban közöltük (92, 93, 94, 95, 96), kezeléseink során 155 
gyermek fogantatása történt meg sikerrel. Tudomásunk szerint a fenti témában elsőként 
közöltünk hazánkban. 
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